

# Stratifying elicited antibody dynamics after two doses of SARS-CoV-2 vaccine in a community-based cohort in Fukushima, Japan

## AUTHORS:

Naotoshi Nakamura<sup>1,†</sup>, Yurie Kobashi<sup>2,3,†</sup>, Kwang Su Kim<sup>1,4,5,†</sup>, Yuta Tani<sup>6</sup>, Yuzo Shimazu<sup>2</sup>, Tianchen Zhao<sup>2</sup>, Yoshitaka Nishikawa<sup>3</sup>, Fumiya Omata<sup>3</sup>, Moe Kawashima<sup>2</sup>, Makoto Yoshida<sup>6</sup>, Toshiki Abe<sup>2</sup>, Yoshika Saito<sup>6</sup>, Yuki Senoo<sup>6</sup>, Saori Nonaka<sup>2</sup>, Morihito Takita<sup>2</sup>, Chika Yamamoto<sup>2</sup>, Takeshi Kawamura<sup>7,8</sup>, Akira Sugiyama<sup>7</sup>, Aya Nakayama<sup>7</sup>, Yudai Kaneko<sup>8,9</sup>, Hyeongki Park<sup>1</sup>, Yong Dam Jeong<sup>1,5</sup>, Daiki Tatematsu<sup>1</sup>, Marwa Akao<sup>1</sup>, Yoshitaka Sato<sup>10</sup>, Shoya Iwanami<sup>1</sup>, Yasuhisa Fujita<sup>1</sup>, Masatoshi Wakui<sup>11</sup>, Kazuyuki Aihara<sup>12</sup>, Tatsuhiko Kodama<sup>8</sup>, Kenji Shibuya<sup>13,14</sup>, Shingo Iwami<sup>1,15,16,17,18,19,†,\*</sup> and Masaharu Tsubokura<sup>2,3,6,20,†,\*</sup>

## AFFILIATIONS:

<sup>1</sup>interdisciplinary Biology Laboratory (iBLab), Division of Natural Science, Graduate School of Science, Nagoya University, Nagoya, Japan. <sup>2</sup>Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima, Japan. <sup>3</sup>Department of General Internal Medicine, Hirata Central Hospital, Fukushima, Japan. <sup>4</sup>Department of Science System Simulation, Pukyong National University, Busan, South Korea. <sup>5</sup>Department of Mathematics, Pusan National University, Busan, South Korea. <sup>6</sup>Medical Governance Research Institute, Tokyo, Japan. <sup>7</sup>Proteomics Laboratory, Isotope Science Center, The University of Tokyo, Tokyo, Japan. <sup>8</sup>Laboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan. <sup>9</sup>Medical & Biological Laboratories Co., Ltd, Tokyo, Japan. <sup>10</sup>Department of Virology, Nagoya University Graduate School of Medicine, Nagoya, Japan. <sup>11</sup>Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan. <sup>12</sup>International Research Center for Neurointelligence, The University of Tokyo Institutes for Advanced Study, The University of Tokyo, Tokyo, Japan. <sup>13</sup>Soma Medical Center of vaccination for COVID-19, Fukushima, Japan. <sup>14</sup>Tokyo Foundation for Policy Research, Tokyo, Japan. <sup>15</sup>Institute of Mathematics for Industry, Kyushu University, Fukuoka, Japan. <sup>16</sup>Institute

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

for the Advanced Study of Human Biology (ASHBi), Kyoto University, Kyoto, Japan.

<sup>17</sup>Interdisciplinary Theoretical and Mathematical Sciences Program (iTHEMS), RIKEN, Saitama, Japan. <sup>18</sup>NEXT-Ganken Program, Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan. <sup>19</sup>Science Groove Inc., Fukuoka, Japan.

<sup>20</sup>Minamisoma Municipal General Hospital, Fukushima, Japan.

†,‡ These authors contributed equally to this study.

\*To whom correspondence may be addressed.

Email: [iwami.iblab@bio.nagoya-u.ac.jp](mailto:iwami.iblab@bio.nagoya-u.ac.jp) (S.I.) and [tsubo-m@fmu.ac.jp](mailto:tsubo-m@fmu.ac.jp) (M.T.).

## 1 **Abstract**

2           Recent studies have provided insights into the effect of vaccine boosters on recall  
3 immunity. Given the limited global supply of COVID-19 vaccines, identifying vulnerable  
4 populations with lower sustained vaccine-elicited antibody titers is important for targeting  
5 individuals for booster vaccinations. Here we investigated longitudinal data in a cohort of 2,526  
6 people in Fukushima, Japan, from April 2021 to December 2021. Antibody titers following two  
7 doses of a COVID-19 vaccine were repeatedly monitored and information on lifestyle habits,  
8 comorbidities, adverse reactions, and medication use was collected. Using mathematical  
9 modeling and machine learning, we stratified the time-course patterns of antibody titers and  
10 identified vulnerable populations with low sustained antibody titers. Moreover, we showed that  
11 only 5.7% of the participants in our cohort were part of the “durable” population with high sustained  
12 antibody titers, which suggests that this durable population might be overlooked in small cohorts.  
13 We also found large variation in antibody waning within our cohort. There is a potential usefulness  
14 of our approach for identifying the neglected vulnerable population.

## 15 Main Text

16 Primary two-dose coronavirus disease 2019 (COVID-19) vaccination leads to rapid  
17 immunity, providing protection against severe acute respiratory syndrome coronavirus 2 (SARS-  
18 CoV-2) infection<sup>1</sup>. Although COVID-19 vaccines still offer good protection against severe disease  
19 and death for months after the second dose owing to the durability of immunity<sup>2-4</sup>, the waning of  
20 vaccine efficacy has become a major concern in the era of “living with COVID-19”<sup>5-9</sup>. The rapid  
21 decline in vaccine-elicited antibodies results in breakthrough infections and adverse health  
22 outcomes caused by emerging variants of concern (VOCs), including the Beta, Delta, and  
23 Omicron variants<sup>10-13</sup>. Additional third and fourth doses of vaccine induce a high-level antibody  
24 response against VOCs<sup>13-17</sup>, implying a need for additional booster vaccinations as a future  
25 pandemic exit strategy<sup>18-20</sup>. Few studies, however, have quantitatively stratified and assessed the  
26 variation in waning of antibody titers at both the population and individual level in a community-  
27 based large cohort.

28 At the population level, it is well known that the older a person is, the faster their protection  
29 weakens after the second vaccination<sup>7,8</sup>, and that people with underlying medical conditions tend  
30 to induce an insufficient antibody response<sup>8,21</sup>. These populations are generally the highest  
31 priority group for booster vaccinations. There is, however, large variation in the vaccine-elicited  
32 antibody response at the individual level, even within the same age group<sup>6-8,15,21,22</sup>. Assessing the  
33 factors that affect such variations will shed further light on our understanding of waning of  
34 protection and identify potentially vulnerable populations that may be a priority for booster  
35 vaccination<sup>8,21</sup>. In the long-run, personalized vaccination will be required, because continuous  
36 vaccinations after the third dose to the whole population may be neither sustainable nor feasible  
37 globally. One approach to assess variation within the same group of people is the stratified  
38 analysis of time-dependent vaccine-elicited antibody dynamics.

39 Although the mean time-dependent vaccine efficacy for symptomatic and severe SARS-  
40 CoV-2 infections has been assessed through cross-sectional and longitudinal studies at the

41 population level<sup>2,3</sup>, many relevant aspects of the individual-level time course of antibody dynamics  
42 and the variations in individual-level dynamics are not well understood. In this study, we collected  
43 longitudinal datasets on individual antibody responses, together with personal information  
44 including lifestyle habits, comorbidities, adverse reactions, and medication use, from more than  
45 2,526 individuals of a community-based cohort in Fukushima, Japan. Taking advantage of this  
46 unique cohort and using mathematical modeling and machine-learning approaches, we stratified  
47 the elicited immune response after two doses of a COVID-19 vaccine by reconstructing individual  
48 antibody dynamics. Furthermore, we explored the factors associated with the durability of vaccine  
49 response. Our aim was to understand individual-level variation in vaccine-elicited immune  
50 responses at the time of booster vaccinations and to inform long-term COVID-19 vaccination  
51 strategies.

## 52 Results


### 53 The Fukushima vaccination cohort

54 This study was conducted from April 2021 to December 2021 in Fukushima, Japan. Our  
55 vaccination cohort consisted of participants from a primarily rural area where COVID-19  
56 prevalence was relatively low: Soma City, Minami Soma City, and Hirata village (**Fig 1A**). The  
57 participants included health care workers, frontline workers, administrative officers, general  
58 residents, and residents of long-term care facilities. In total, 2,526 participants who had been  
59 vaccinated with the Pfizer BNT162b2 or Moderna mRNA-1273 vaccine were recruited, and 2,159  
60 participants were included in the final data analysis, respectively (see **Fig 1B** and **Methods** in  
61 details). The age and sex distributions of the participants are shown in **Fig 1C**, and the sample  
62 characteristics and information on adverse vaccine events stratified by age are provided in  
63 **Extended Data Table 1**. A portion of this cohort was described previously for the time period  
64 extending to 6 months after the first dose of mRNA vaccine<sup>23,24</sup>.

65 Here we investigated antibody titers in the Fukushima cohort in individuals sampled  
66 longitudinally (serum was collected at 2 or 3 different timepoints) for around 4 to 9 months after  
67 the second primary dose of mRNA vaccine (see **Fig 1DE** for details). Notably, the number of  
68 SARS-CoV-2 infections in this rural area was extremely low (**Fig 1E**), so that we could minimize  
69 the influence of breakthrough natural infections. The Fukushima cohort, which is large enough  
70 and with a long study period (**Fig 1F**), is an ideal longitudinal cohort for quantifying and stratifying  
71 vaccine-elicited antibody dynamics (**Supplementary Note 1** and **Supplementary Table 1**). In  
72 particular, compared with the largest cohort of more than 3,900 participants from Israel,<sup>6</sup> the  
73 Fukushima cohort is community-based, includes non-health workers, has very few dropouts  
74 among more than 2,000 identical individuals who were consecutively sampled (only 3.3%),  
75 includes all necessary information for all participants, and includes measures of several  
76 modalities of antibody titers including neutralizing activity (**Supplementary Table 2**).

77 We performed chemiluminescent immunoassay (CLIA) to measure antibody titers as a  
78 measure of humoral immune status after the first COVID-19 vaccination (i.e., a total of 5195

79 IgG(S), 5195 neutralization activity, and 4969 IgG(N) assays were performed) (**Methods**). **Fig 1G**  
80 shows the overall profile of IgG(S) and neutralization activity in this study. We investigated  
81 longitudinal data for IgG(S) in the same individuals because IgG(S) covers a wider range of  
82 antibody responses and is more sensitive than neutralization activity. In fact, these two  
83 measurements are highly correlated with each other (correlation coefficient of 0.93) (**Extended**  
84 **Data Fig 1AB**), and previous studies showed that neutralizing antibody and IgG(S) titers correlate  
85 with vaccine-mediated protection, even against VOCs (i.e., vaccine efficacy)<sup>1-3</sup>. This is because  
86 vaccines containing the original Wuhan virus spike protein induce variant-reactive memory B cells  
87 targeting multiple different VOCs, including the Omicron variant<sup>15</sup>.



88 **Figure 1 | Characteristics of the Fukushima vaccination cohort: (A)** Locations of Soma city,  
 89 Minami Soma city, and Hirata village in Fukushima prefecture are described. **(B)** Flowchart of the  
 90 vaccination cohort along with the number of participants, testing, and inclusion criteria for our  
 91 analysis are described. **(C)** Age and sex distributions in the cohort are shown. **(D)** Timeline of  
 92 sample collection for each cohort participant (N=2,526 participants, 5195 total samples) is  
 93 described. The timings of blood samplings are indicated in black circles. Shaded areas indicate  
 94 early (<89 days), middle (90-179 days), and late (>180 days) time periods after the first  
 95 vaccination. Dates for the second vaccination are shown as the distributions in the bottom panel.  
 96 **(E)** Vaccination and blood sampling periods in the cohort along with the number of COVID-19  
 97 cases (i.e., cases) in Soma city, Minami Soma city, and Hirata village<sup>48,49</sup> are shown. **(F)**  
 98 Distribution of the study periods and the number of participants (i.e., cohort size) of previously  
 99 reported cohorts extracted by literature review (**Supplementary Note 1**) are plotted along with  
 100 the Fukushima vaccination cohort (the red mark). The closed and open marks correspond to  
 101 cohorts with and without questionnaire data. The origin of coordinates corresponds to the  
 102 median of the period and number of the cohorts, and the whiskers indicate corresponding  
 103 standard derivations. **(G)** Longitudinal IgG(S) and neutralizing activity measured by CLIA are  
 104 separately plotted by time after the first vaccination and age.



## 105 Stratification of vaccine-elicited time-course antibody dynamics

106 We developed a mathematical model describing the vaccine-elicited antibody dynamics  
107 to evaluate the impact of primary two-dose COVID-19 vaccination on rapid immunity at the  
108 individual level and reconstructed the best-fit antibody titer curves of 2,407 participants in the  
109 Fukushima cohort (details are provided in the **Methods**). We then performed an unsupervised  
110 clustering analysis using a random forest dissimilarity to stratify the time-course patterns of  
111 antibody dynamics into six groups (i.e., G1 to G6) (details in **Supplementary Note 2**). **Fig 2A**  
112 represents a two-dimensional Uniform Manifold Approximation and Projection (UMAP)  
113 embedding of these six groups, which clearly shows that G5 and G6 are separated from the other  
114 groups. Using a different color for each group, we also plotted the reconstructed individual  
115 antibody dynamics after 25 days after the first vaccination as shown in **Fig 2B** (see also **Extended**  
116 **Data Fig 2D**). The projected time course of each group showed that sustained antibody titers  
117 remained high among individuals in G1 (i.e., the “rich” responder group), whereas those in G5  
118 and G6 were low (i.e., “poor” responders) (**Fig 2C**). We classified G1 as a “durable” population  
119 and G5/G6 as a “vulnerable” population in our analysis. In contrast, individuals in G2, G3, and G4  
120 showed intermediate dynamics. Note that most individuals in the Fukushima cohort had no history  
121 of natural infection (i.e., only 1.07%).


122 Next, we investigated the age dependency of the 6 groups (**Fig 2D**): G1/G2, G3/G4, and  
123 G5/G6 consisted mainly of people aged 0 to 39 years (young), 40 to 64 years (middle age) and  
124 65 to 100 years (old), respectively. Most individuals were stratified into G3 or G2, the  
125 representative population of the Fukushima cohort (**Fig 2E**). Although the age distributions of  
126 G1/G2 and G3/G4 were similar, individuals in G2 and G4 showed a relatively rapid decay in  
127 antibody response after the second dose compared with those in G1 and G3, respectively  
128 (**Extended Data Fig 2D**).

129 The longitudinal IgG(S) and neutralizing activity measured by CLIA are separately plotted  
130 into three different periods (i.e., 0-89, 90-179,  $\geq 180$  days) by taking into account the stratified  
131 groups in **Fig 2F**. Both IgG(S) and neutralizing activity decreased as age increased and time

132 passed. More precise predictions (i.e., at a specific date at an individual level rather than during  
133 a specific period at a population level) were made possible with our reconstructed individual-level  
134 antibody dynamics (**Fig 2G**).

135 To further evaluate the vaccine-elicited immunity, we calculated the fraction of individuals  
136 with antibody titers of IgG(S) below set thresholds (i.e., 10 and 200 arbitrary unit/mL [AU/mL])  
137 (**Fig 2H**). As reported in the study by Nakano et al.<sup>25</sup>, 10 AU/mL is a clear threshold for  
138 unvaccinated individuals, meaning that individuals showing titers less than this threshold have no  
139 vaccine efficacy at all. In contrast, so far, there are no clear thresholds for quantifying vaccine  
140 efficacy, as intensively discussed in Cromer et al.<sup>2</sup> and Khoury et al.<sup>3</sup>. Here we used the value of  
141 200 AU/mL as an indicator for the efficacy threshold, because more than 80% of vaccinated  
142 persons maintained their antibody titers above 200 AU/mL during the early period (i.e., for at most  
143 3 months after the first vaccination) regardless of group in our cohort (see the top-left panel in **Fig**  
144 **2F**). Our simulations showed that most of the durable population (i.e., G1) maintained their  
145 vaccine efficacy for at least 8 months, and furthermore, around 13% of them still did not show a  
146 loss of vaccine efficacy for 1 year after the first vaccination (**Fig 2H**). On the other hand, the  
147 vulnerable populations (i.e., G5/G6) showed a low induction of antibody titers after the second  
148 dose and rapid decay in efficacy; approximately 50% of them had very low antibody titers after 1  
149 year, which were comparable to those in unvaccinated persons. Individuals in G4 showed a high  
150 initial induction of antibody titers after the second dose but a rapid decay; approximately 95% of  
151 them showed a loss of vaccine efficacy after 1 year.

152 For our sensitivity analysis, we used the threshold of 80 AU/mL, which corresponds to  
153 “strong positive” as defined in the Mount Sinai Health System<sup>26</sup> and obtained the same  
154 conclusions (e.g., **Supplementary Fig 1A** for 80 AU/mL).




**Figure 2 | Stratification of vaccine-elicited antibody response: (A)** UMAP of stratified antibody responses to mRNA vaccination based on the extracted features from the reconstructed individual-level antibody dynamics are shown. Data points represent individual participants and are colored according to group (i.e., G1 to G6). **(B)** The reconstructed individual antibody dynamics after 25 days after the first vaccination in each group are shown. **(C)** The time-course patterns highlighted by Partial Least-Squares Discriminant Analysis (PLS-DA), which discriminates each group from the others, are shown. The individual dynamics after 25 days after the first vaccination were projected onto the direction of the first latent variable. The horizontal dashed lines at 200 and 10 AU/mL correspond to the thresholds of “vaccine efficacy” and unvaccinated persons, respectively. The vertical dotted lines represent 180 and 240 days after the first vaccination. **(D)** Age distribution in each group along with its fraction (%) and the number of individuals (n) is shown. **(E)** Group distribution by age (i.e., 0-39, 40-64, 65-100) is plotted in pie charts. **(F)** Measured IgG(S) and neutralizing activity in each group are plotted in the early, middle, and late period. **(G)** Simulated IgG(S) titers from reconstructed individual-level antibody dynamics at 60, 180, and 240 days after the first vaccinations are plotted. **(H)** Fraction of individuals with antibody titers <10, 10-200, and 200 < AU/mL in each group at 180, 240, and 365 days are plotted as black, white, and group color, respectively, in pie charts. All correlations were calculated as Pearson correlation coefficients.

## 174 **Characterizing vulnerable and durable populations**

175 Multiple factors, including underlying medical conditions, drug history, and immune  
176 competency, may contribute to the stratification of the study population. For example, there was  
177 substantial variation in sustained immunity within the same age group (e.g., age distributions in  
178 both the durable and vulnerable populations were wide), and about 7% of the vulnerable  
179 population in G5/G6 were young individuals (0-39 years of age) (**Fig 2E**).

180 To further characterize each stratified group, we trained a random forest classifier to  
181 predict the group from the sample characteristics of 2159 individuals in the Fukushima cohort  
182 (see **Extended Data Table 1**), and obtained ROC-AUCs of 64.4%, 69.3%, and 70.9% for  
183 predicting G1 (the durable population), G2, and G1/G2, respectively (**Fig 3A**). Analysis of the  
184 feature importance suggested that adverse reactions (e.g., headache and joint pain) were  
185 significant predictors common to both G1 and G2 (**Fig 3C**). On the other hand, we achieved ROC-  
186 AUCs of 78.0%, 75.1%, and 80.8% for predicting G5, G6, and G5/G6 (the vulnerable populations),  
187 respectively (**Fig 3B**). Various factors including age, the interval between the two doses,  
188 comorbidities, and medication use were listed as the significant predictors of G5 and/or G6 (**Fig**  
189 **3D**). This finding was consistent with the results of our literature review (see **Supplementary**  
190 **Table 3**). We were not able to achieve a high ROC-AUC for predicting G3 and G4, the groups  
191 into which the majority of our cohort participants fell (see **Extended Data Fig 3A** and **Discussion**).

192 Furthermore, when the classifier for G5/G6 was trained after the population was stratified  
193 according to age (i.e., 0-39 [young], 40-64 [middle age], and 65-100 [old]), the ROC-AUCs were  
194 69.3%, 68.7%, and 70.1%, respectively (see **Extended Data Fig 3B**). Our analysis of the feature  
195 importance suggested that medication use (e.g., anti-cancer agents, steroids, and  
196 immunosuppressants) was a significant predictor for young people, whereas alcohol consumption  
197 and smoking played an additional role for middle-aged persons (**Fig 3E**). The detailed inter-  
198 relationship of the various features described in **Fig 3F** and **Extended Data Fig 3C** are explained  
199 in **Supplementary Note 3**.



**Figure 3 | Characterization of vulnerable and durable populations:** (A) and (B) show the ROC curves of random forest classifiers trained on predicting either G1 (durable population); G2 or G1/G2; and G5, G6, or G5/G6 (vulnerable population), respectively. The corresponding AUC value of each ROC curve is calculated on the top of each panel. (C) and (D) show the most predictive features (feature importance) of G1, G2, and G1/G2 and G5, G6, and G5/G6 as Chord diagrams, respectively. Each feature is represented by a fragment on the outer part of the circular layout. The size of the arc from a group to a feature is proportional to its importance as measured by mean decrease in accuracy. Features with  $p < 0.05$  are displayed. (E) The most predictive features of G5/G6 in young, middle-aged, and old populations are calculated and shown as a Chord diagram. Features with  $p < 0.05$  are displayed. (F) Principal component analysis of various features is shown. The colored ellipses represent 90% data ellipses drawn for each category.

## 212 **Predicted effect of booster vaccination on stratified antibody dynamics**

213 Several studies have reported that booster doses after the primary two-dose vaccination  
214 rapidly increase antibody titers to a high level, and that these booster-elicited antibody responses  
215 induce substantial neutralization against VOCs, including the Omicron variant<sup>15-17</sup>. However, it  
216 remains unclear how booster vaccinations shape the induction of antibody response depending  
217 on the second-dose, vaccine-elicited antibody dynamics (i.e., the time-dependent vaccine-elicited  
218 antibody history). Despite the current limited vaccine supply and large variation even within the  
219 same stratified group, the priority for booster vaccines at the “individual level” of immunity and the  
220 effect of boosters on “population-level” immunity are not well understood.


221 Assuming similar immune kinetics of the second-dose, vaccine-elicited antibody  
222 dynamics, we modeled the elicited antibody responses on each group over the first year after the  
223 booster vaccination at 8 months after the first vaccination (**Fig 4A**). Consistent with the current  
224 booster vaccination studies<sup>13,14,16-20,27</sup>, our simulations showed a rapid and high induction of  
225 antibody responses regardless of group. Moreover, our simulation supported that a third-dose  
226 vaccination booster protects against VOCs in a wide range of populations. In contrast, 35% and  
227 9% of G5 and G6, respectively, at 1 month after booster vaccination showed limited induction (i.e.,  
228 less than 200 AU/mL) (see **Fig 4B**). We also confirmed a similar trend for booster vaccination at  
229 1 year (**Extended Data Fig 4A**), and at the threshold of 80 AU/mL at 8 months (**Supplementary**  
230 **Fig 1B**). The existence of these vulnerable populations may explain the considerable variability  
231 in booster-elicited antibody responses observed in several cohort studies<sup>6-8,15</sup>. Targeting  
232 individuals in G5/G6 for booster vaccination is expected to provide protection from breakthrough  
233 infection.

234 Next, taking advantage of our stratification, we further evaluated the effect of booster  
235 vaccination on population-level immunity. Here we assumed a hypothetical cohort of 10,000  
236 individuals, adjusted for age and sex distributions according to population estimates in Japan as  
237 of 1 July 2021 by the Statistics Bureau of Japan, Ministry of Internal Affairs and Communications<sup>28</sup>

238 **(Fig 4C)**. We excluded populations aged less than 12 years in our simulations to reflect the age  
239 threshold of the cohort.

240 First, we simulated the fraction of individuals with antibody titers below the thresholds (i.e.,  
241 10 and 200 AU/mL) when all individuals received a booster vaccine (i.e., 100% booster coverage)  
242 at different time periods (8 and 12 months after the first vaccination) in **Extended Data Fig 4BC**.  
243 As expected, 100% booster coverage effectively increases and recovers their immune responses  
244 regardless of timing compared with the no booster scenario. Since 100% booster coverage is too  
245 optimistic given the limited vaccine supply, we next applied more realistic booster strategies: 20%  
246 and 50% coverage of booster vaccinations (**Fig 4DE** and **Extended Data Fig 4DE**). We compared  
247 the booster vaccinations to 2,000 individuals (i.e., 20% of the total 10,000 population: 20% booster  
248 vaccination) in G1/G2 (green curve: the durable population and others), G5/G6 (red curve: the  
249 vulnerable population), and randomly sampled groups (blue curve) in **Fig 4DE**. Although small  
250 differences were observed for the fraction with the threshold of 200 AU/mL (**Fig 4D**), the booster  
251 vaccinations provided similar benefit to population-level immunity regardless of population  
252 clusters. Similar trends in 50% booster coverage are shown in **Extended Data Fig 4DE**. Here we  
253 again stress that the same conclusions are obtained with different thresholds instead of 200  
254 AU/mL (e.g., **Supplementary Fig 1CDE** for 80 AU/mL). Considering the relative benefit of booster  
255 vaccinations at the individual level, our identified vulnerable population is a candidate for priority  
256 booster vaccination under the limited vaccine supply (see **Discussion**).

257



258 **Figure 4 | Simulating booster vaccines: (A)** Predicted individual elicited antibody responses for  
 259 each group over the first year after booster vaccination at 8 months after the first vaccination are  
 260 shown. The horizontal dashed and vertical dotted lines correspond to 200 and 10 AU/mL and at  
 261 180 and 240 days after the first vaccination, respectively. **(B)** Fraction of individuals with antibody  
 262 titers of <10, 10-200, and 200 < AU/mL in each group at 1 month after booster vaccination are  
 263 plotted as black, white, and group color, respectively, in pie charts. **(C)** Age and sex distributions  
 264 of a hypothetical cohort adjusted via population estimates in Japan are shown along with those  
 265 in the Fukushima vaccination cohort. **(D)** and **(E)** show the time-dependent fractions of individuals  
 266 with antibody titers above 200 and 10 AU/mL with (i.e., colored curves) and without (i.e., black  
 267 dashed curve) 20% booster vaccination at 240 days after the first vaccination, respectively. The  
 268 green, blue, and red curves correspond to the booster vaccination targeting individuals randomly  
 269 sampled from G1/G2, G1-G6, and G5/G6, respectively. Enlarged view of the dotted box in **(D)**  
 270 shows the fraction plotted in log-scale.



## 271 Discussion

272 As of May 6, 2022, there were 266 COVID-19 vaccine candidates undergoing phase 1/2  
273 clinical trials and 124 candidates in phase 3 clinical trials (ClinicalTrials.gov). However, it is  
274 expected to take more time until second-generation vaccines that block transmission of Omicron  
275 and other novel virus variants with a much higher probability than current ones are available  
276 around the world. We still need to use the current first-generation vaccines as vaccine boosters.  
277 Therefore, determining the priority for booster vaccines in the vulnerable population is an  
278 important public health concern given a limited global supply of vaccines<sup>13-20</sup>.

279 In this study, we aimed to understand the individual-level variation in vaccine-elicited  
280 immune responses at the time of booster vaccinations and the effect of booster vaccination. Only  
281 1.07% of our cohort of individuals had a history of natural infection; thus, the influence of natural  
282 infection was minimal in the present study. We repeatedly assessed and monitored antibody titers  
283 following two doses of a SARS-CoV-2 vaccine in the unique Fukushima cohort of 2,526  
284 individuals.

285 Previous studies generally investigated differences in vaccine-elicited antibody  
286 responses after stratification of the population according to variables including age, sex, lifestyle  
287 habits, comorbidities, adverse reactions, and medication use (i.e., in “given” groups). For example,  
288 Levin and colleagues explored differences in antibody responses according to age, sex, and  
289 immunosuppression<sup>8</sup>. Ward and colleagues also showed that antibody responses are significantly  
290 decreased in individuals with diabetes, obesity, smoking habits, cancer, immunosuppression, or  
291 neurological conditions after adjustment for age and sex<sup>29</sup>. It is well known that active cytotoxic  
292 chemotherapy and specific comorbidities such as kidney disease, hypertension, and heart  
293 disease significantly affect antibody responses<sup>22,30-32</sup>. Importantly, in our cohort, we identified six  
294 groups with different antibody responses by using a combined approach with process-based  
295 mathematical modeling and data-driven analysis (i.e., without determining these “given” groups  
296 in advance as mentioned above). In particular, we found that G1 mainly consisted of participants  
297 aged 0 to 39 years who were part of the durable population (i.e., those who were “rich” responders

298 showing high sustained antibody titers), whereas G5/G6 consisted of participants aged 65 to 100  
299 years who were part of the vulnerable population (that is, those who were “poor” responders  
300 showing low sustained antibody titers). Our study showed that more than 10% of the durable  
301 population maintained their IgG(S) titers above 200 AU/mL for 1 year after the first vaccination,  
302 whereas approximately 50% of the vulnerable population could not maintain their antibody titers  
303 above 10 AU/mL after 1 year (i.e., they completely lost their vaccine efficacy).

304 An important question is how we maintain both individual- and population-level immunity  
305 through booster vaccinations. Although T and B cell responses may contribute to protection from  
306 symptomatic and severe infections<sup>4,12,27,33</sup>, recent studies have shown that vaccine efficacy is  
307 strongly linked to the elicited antibody responses, meaning that sustained high antibody titers  
308 above a certain threshold are crucial<sup>2,3,34</sup>. The present study showed that vulnerable populations  
309 (i.e., G5/G6) include individuals who are not necessarily older adults nor with high-risk conditions.  
310 In fact 5.5% of G5/G6 were young adults who did not have any underlying medical conditions but  
311 reported at least one adverse reaction. Although there is no clear consensus for the threshold so  
312 far, we found that individuals in G4 maintained high antibody titers induction for months, but their  
313 titers rapidly decreased below 200 and 80 AU/mL around 6 and 7 months after the first dose on  
314 average, respectively. Because individuals who are classified in G4, G5, and G6 represent those  
315 with poor or rapidly decaying vaccine-elicited antibody responses who would not necessarily  
316 benefit from the current prioritized booster program on the basis of age and prior medical  
317 conditions, it may be important to better understand the large variation in vaccine-induced  
318 immunity at the individual level as shown in the present study. Identifying these target individuals  
319 and recruiting them to booster vaccinations are important tactics.

320 Most of the durable population (i.e., G1) will maintain their antibody titers induced by the  
321 second dose of mRNA vaccine at high levels at least for 8 months after the first dose, implying  
322 that the priority for booster vaccinations is low. Individuals in G1 had no history of natural infection  
323 except for one participant. In our study cohort, G1 made up only 5.7% of the cohort, and we only  
324 identified these participants because of the large participant size of the Fukushima cohort (over

325 2,500 individuals). In other words, if the cohort size was in the range of several hundreds, which  
326 is the usual size of prior studies made up of health care workers volunteers<sup>30,35-38</sup> (e.g., 93.5% of  
327 93 cohort studies in our literature review had less than 1,000 participants, see **Supplementary**  
328 **Note 1**), these durable individuals might not have been identified and might have been overlooked  
329 as outliers (e.g., around 5 individuals in a cohort of 100 individuals). Although the  
330 representativeness of the small cohort is unclear (only 61 individuals), preexisting high antibody  
331 titers before booster vaccination may limit the extent of antibody boosting (see below)<sup>15</sup>.

332 Our study suggests that booster vaccination of the vulnerable populations of G5/G6 at 80  
333 days after the first vaccination increases antibody titers at both the individual and population level.  
334 Booster vaccinations added similar effects to population-level immunity regardless of a population  
335 profile under the limited vaccine supply (i.e., 20% and 50% booster coverage) in our simulations.  
336 These scenario-based simulations provide novel insights on the timing for booster vaccinations  
337 to maintain both individual- and population-level immunity against the emerging and future VOCs.

338 Overall, our analysis showed a large variation in vaccine-elicited antibody response at the  
339 individual level<sup>6-8</sup>. Additional work is required to evaluate how specific antibody neutralizations of  
340 VOCs, as quantified by live virus, influence the stratification<sup>13,15,27</sup>, and how vaccine-elicited  
341 cellular immunity, including B and T cell responses, would explain such variations<sup>12,15</sup>. In particular,  
342 we used only the basic demographic information for the characterization of the six groups and  
343 are currently collecting additional longitudinal immunologic information, such as cellular immune  
344 changes (e.g., memory B cell compartments) and cytokine and chemokine profiles of the  
345 vaccinated individuals in our cohort. This will enable us to test and further characterize and  
346 understand durability and vulnerability in G1 and G5/G6, respectively<sup>15</sup>.

347 There is an assumption in our mathematical model underlying the vaccine-elicited  
348 antibody response: antibodies are simply assumed to be generated from one compartment of B  
349 cells including heterogeneous cell populations that produce antibodies. That is, our mathematical  
350 model describes the vaccine-elicited antibody responses induced by the average B cell  
351 populations. As additional datasets become available on time course and quantitative phenotypic

352 B cell populations such as short-lived antibody-secreting cells (i.e., plasmablasts), long-lived  
353 antibody-secreting cells (i.e., plasma cells), and SARS-CoV-2-specific (class-switched) memory  
354 B cells,<sup>9,39</sup> it will be necessary to adjust our mathematical model to more precisely differentiate  
355 the antibody dynamics of different B cells. In a recent study with a small sample size, the decay  
356 rate of S-specific IgG from its peak to around 6 months after the first dose was similar, but the  
357 average decay slowed between 6 and 9 months<sup>15</sup>. Other studies suggest that germinal center B  
358 cell responses are critical to maintain the longevity of sustained antibody titers apart from the  
359 quick and large antibody production immediately after the second vaccination (or infection)<sup>40-42</sup>.  
360 Although this emerging evidence for the heterogeneity of B cell populations implies that the two-  
361 compartment model of antibody-secreting cells (i.e., plasmablasts and plasma cells) may better  
362 describe IgG(S) dynamics, our mathematical model describes the IgG(S) dynamics of 2,159  
363 individuals (of which 208 individuals had 3 samples collected) at least until around 9 months after  
364 the first dose. Our stratification is based on feature engineering but not reconstructed antibody  
365 dynamics directly, meaning that the effect of the late-phase dynamics is minimal. However, long-  
366 term prediction of antibody dynamics by use of our mathematical model will not be possible.

367         Important research questions remain: whether people will be classified into the same (or  
368 similar) stratified groups after booster vaccination, how the booster vaccine-elicited antibody  
369 response will change depending on the interval between the second and third doses, and which  
370 group shows low and high neutralization to (emerging) VOCs, for example. The Fukushima cohort  
371 is an ideal environment in which to evaluate how immunity, including humoral and cellular  
372 responses of durable and vulnerable individuals, is increased by future SARS-CoV-2 infections  
373 after the booster vaccination. Taking advantage of our Fukushima cohort, we will further evaluate  
374 the impact of booster vaccinations and post-vaccination infections on the identified vulnerable  
375 populations<sup>43,44</sup>.

## 376 METHODS

### 377 Ethics statement

378 The study was approved by the ethics committees of Hirata Central Hospital (number  
379 2021-0611-1) and Fukushima Medical University School of Medicine (number 2021-116). Written  
380 informed consent was obtained from all participants individually before the survey.

### 382 Participant recruitment and sample collection

383 The candidates were mainly recruited from Hirata village, Soma city, and Minamisoma  
384 city in rural Fukushima prefecture. We conducted sequential blood sampling and non-sequential  
385 blood sampling. Twelve health care workers participated in the sequential blood sampling, and  
386 their vaccination and blood sampling schedule are shown in **Fig 1E**. A total of 2526 individuals  
387 participated in non-sequential blood sampling. Health care workers, frontline workers, and  
388 administrative officers from each municipality were intentionally recruited to keep the cohort size  
389 large and the dropout rate low. Although most of the health care workers, frontline workers, and  
390 administrative officers were under the age of 65, relatively healthy community-dwelling older  
391 adults living in the community and in long-term care facilities were also recruited to maintain a  
392 wide age range for the cohort. Blood sampling was performed once during each period in June,  
393 September, and November 2021, respectively. The first vaccine dose was administered between  
394 March 10 and August 20, 2021, and the second dose between March 31 and September 14. The  
395 median (interquartile range) interval for the two-dose vaccination was 21 days. A total of 226  
396 health care workers participated in the first blood sampling between May 31 and June 6, 2021. A  
397 total of 2526 individuals participated in the second blood sampling between September 8 and  
398 October 8, 2021. A total of 2443 individuals participated in third blood sampling between  
399 November 21 and December 25, 2021 (**Fig 1E**). Note that the 12 health care workers (described  
400 in **Extended Data Fig 5B**) with sequential blood sampling were not included in the non-sequential  
401 population of 2526 participants. In conclusion, of the total 2526 participants, those eligible for  
402 analysis were those who completed the second vaccination and at least two blood samplings.

403 Participants whose antibody titer was higher than in the previous blood sampling in non-sequential  
404 blood sampling were excluded from the final analysis (**Fig 1B**).

405 Information on sex, age, daily medication, medical history, date of vaccination, adverse  
406 reaction after vaccination, type of vaccination, blood type, bacillus Calmette–Guérin (BCG)  
407 vaccine history, smoking habit, and drinking habit was retrieved from the paper-based  
408 questionnaire (summarized in **Extended Data Table 1**). All blood sampling was performed at the  
409 medical facilities with 8 mL, and serum samples were sent to The University of Tokyo.

410

### 411 **SARS-CoV-2-specific antibody measurement**

412 All serological assays were conducted at The University of Tokyo. Specific IgG (i.e.,  
413 IgG(S)) and neutralizing activity were measured as the humoral immune status after COVID-19  
414 vaccination. Specific IgG antibody titers (IgG(N)) were used to determine past COVID-19 infection  
415 status. Chemiluminescent immunoassay with iFlash 3000 (YHLO Biotech, Shenzhen, China) and  
416 iFlash-2019-nCoV series (YHLO Biotech, Shenzhen, China) reagents were used in the present  
417 study. The threshold value was 10 AU/mL. The measurement range was 2-3500 AU/mL for IgG(S)  
418 and 4-800 AU/mL for neutralizing activity. For neutralizing activity, AU/mL×2.4 was used to  
419 convert to International Units (IU/mL); for IgG(S), AU/mL×1.0 was used to convert to binding  
420 antibody units (BAU/mL). The testing process was as per the official guideline. Quality checks  
421 were conducted every day before starting the measurement.

422

### 423 **Mathematical modeling of (booster) vaccine-elicited antibody dynamics**

424 We developed a simple but quantitative mathematical model describing the vaccine-  
425 elicited antibody dynamics as follows:

$$426 \quad \frac{dM_i(t)}{dt} = \begin{cases} 0 & (t < \tau_i) \\ -dM_i(t) & (t \geq \tau_i) \end{cases} \quad (1)$$

$$427 \quad \frac{dB(t)}{dt} = P_i(t) \frac{M(t)^m}{K^m + M(t)^m} - \mu B(t), \quad (2)$$

$$\frac{dA(t)}{dt} = pB(t) - cA(t), \quad (3)$$

where the variables  $M_i(t)$ ,  $B(t)$ , and  $A(t)$  are the amount of mRNA inoculated by the  $i$ -th vaccination, the number of antibody-secreting cells, and the antibody titers at time  $t$ , respectively. Parameters  $\tau_i$  and  $d$  represent the timing of the  $i$ -th vaccination and the decay rate of mRNA. Note that  $\tau_1 = 0$  is assumed for all individuals and  $\tau_2 - \tau_1$  corresponds to the interval of the first and second vaccinations. We here considered that  $D_i$  is the inoculated dose of mRNA by the  $i$ -th vaccination, that is,  $M_i(\tau_i) = D_i$  for  $i = 1, 2, \dots, n$ , and  $M(t) = \sum_{i=1}^n M_i(t)$ .

In our mathematical model, one compartment of B cells including heterogeneous cell populations that produce antibodies is assumed, and therefore the product of  $P_i(t)$  and  $M(t)^m / (M(t)^m + K^m)$  represents the average *de novo* induction of the antibody-secreting cells, that is, the average B cell population dynamics is modeled. Here  $P_i(t)$  is a step function defined as  $P_i(t) = P_i$  for  $\tau_i + \eta_i \leq t < \tau_{i+1} + \eta_{i+1}$ , where  $\eta_i$  is the delay of induction of the antibody-secreting cells after the  $i$ -th vaccination: otherwise  $P_i(t) = 0$ . The parameters  $m$ ,  $K$ , and  $\mu$  correspond to the steepness at which the induction increases with increasing amounts of mRNA (i.e., the hill coefficient), the amount of mRNA satisfying  $P_i/2$ , and the average decay rate of the antibody-secreting cell compartment, respectively.

For example, after the first vaccination, antigen-specific B cells expand and induce antibody-secreting cells and memory B cells. This rapid immune response regarding expansion and induction is formulated by the function of  $P_1 M_1(t)^m / (M_1(t)^m + K^m)$  for  $\eta_1 \leq t < \tau_2$ . On the other hand, after the second vaccination, the memory B cells are reactivated by re-exposure to antigen, and this reactivation induces antibody-secreting cells, increases the number of memory B cells, and further re-establishes B cell memory. The recall B cell responses and their antibody secretion are described by the function of  $P_2 (M_1(t) + M_2(t))^m / ((M_1(t) + M_2(t))^m + K^m)$  for  $\tau_2 + \eta_2 \leq t$ . The quantity and quality of memory B cells established by the second vaccination are considered in  $P_2$ . In a similar manner, the recall B cell responses by the vaccine booster (i.e., the third dose) are simply described by  $P_3 (M_1(t) + M_2(t) + M_3(t))^m / ((M_1(t) + M_2(t) + M_3(t))^m +$

454  $K^m$ ) for  $\tau_3 + \eta_3 \leq t$ . Note that  $P_2 = P_3$ ,  $\eta_2 = \eta_3$  are assumed in our booster simulations. The  
455 other parameters,  $p$  and  $c$ , represent the antibody production rate and the clearance rate of  
456 antibodies, respectively.

457 Since the clearance rate of antibody is much larger than the decay of antibody-secreting  
458 cells, we made a quasi-steady state assumption,  $dA(t)/dt = 0$ , and replaced Eq.(3) with  $A(t) =$   
459  $pB(t)/c$ . Thus, we obtained the following simplified mathematical model, which we used to  
460 analyze the antibody responses in this study (see **Extended Data Fig 5A**):

$$461 \quad \frac{dM_i(t)}{dt} = \begin{cases} 0 & (t < \tau_i) \\ -dM_i(t) & (t \geq \tau_i) \end{cases} \quad (4)$$

$$462 \quad \frac{dA(t)}{dt} = H_i(t) \frac{M(t)^m}{K^m + M(t)^m} - \mu A(t), \quad (5)$$

463 where  $H_i(t) = H_i = pP_i/c$  for  $\tau_i + \eta_i \leq t < \tau_{i+1} + \eta_{i+1}$ . In our analysis, the variable  $A(t)$   
464 corresponds to the IgG(S) titers (AU/mL).

465

## 466 **Quantifying vaccine-elicited time-course antibody dynamics**

467 In addition to the participants in the cohort, we included 12 health care workers whose  
468 serum was sequentially sampled for 40 days (on average 25 samples per individual) for validation  
469 and parameterization of a mathematical model for vaccine-elicited antibody dynamics. A  
470 nonlinear mixed effects model was used to fit the antibody dynamics model, given by Eqs.(4-5),  
471 to the longitudinal antibody titers of IgG(S) obtained from the 12 health care workers. The  
472 mathematical model included both a fixed effect and a random effect in each parameter. That is,  
473 the parameters for individual  $k$ ,  $\theta_k (= \theta \times e^{\pi_k})$ , are represented as a product of  $\theta$  (a fixed effect)  
474 and  $e^{\pi_k}$  (a random effect).  $\pi_k$  follows a normal distribution with mean 0 and standard deviation  
475  $\Omega$ . We here assumed that the parameters  $H_1, H_2, \eta_1, \eta_2$ , and  $m$  varied across individuals,  
476 whereas we did not consider interindividual variability in other parameters to ensure parameter  
477 identifiability. Note that the half-life of mRNA (i.e.,  $\log 2 / d$ ) and dose of mRNA (i.e.,  $D_i$ ) are  
478 assumed to be 1 day<sup>45</sup> and 100 ( $\mu\text{g}/0.5\text{mL}$ )<sup>46</sup>, respectively. Fixed effect and random effect were



479 estimated by using the stochastic approximation expectation-approximation algorithm and  
480 empirical Bayes' method, respectively. Fitting was performed using MONOLIX 2019R2  
481 ([www.lixoft.com](http://www.lixoft.com))<sup>47</sup>. The estimated (fixed and individual) parameters are listed in **Supplementary**  
482 **Table 4**. Interestingly, we found that most of the best-fitted estimated parameters in the  
483 mathematical model (i.e.,  $D_1$ ,  $D_2$ ,  $d$ ,  $\mu$ ,  $K$ ,  $\eta_1$ ,  $\eta_2$ ,  $H_1$ ) were the same or similar across the 12  
484 individuals compared with those of parameters of  $m$  and  $H_2$  (see **Supplementary Table 4**). We  
485 note that  $m$  and  $H_2$ , which showed wide variation of estimated values, contributed mainly to the  
486 vaccine-elicited antibody dynamics after the second vaccination, whereas the other parameters  
487 contributed to that after the first dose.

488 Since 2,407 participants had only 2 or 3 measurements of antibody titers at different time  
489 points, we hereafter fixed the parameters in our mathematical model to be the estimated  
490 population parameters listed in **Supplementary Table 4**, except  $m$  and  $H_2$ , to accurately  
491 reconstruct the large variations in antibody dynamics after the second dose, and these two  
492 parameters were independently estimated from each IgG(S) by a nonlinear least-squares method.  
493 Although the variation in the 12 individuals may not cover the whole variation of the antibody  
494 induction dynamics after the first dose, our analysis focused on those after peak, and the results  
495 on the stratification (in particular, the durable and vulnerable populations) are expected to be the  
496 same. Using the estimated parameters for each individual, we fully reconstructed the dynamics  
497 of IgG(S) titers after the first vaccination (**Extended Data Fig 5B**). We summarized the distribution  
498 of parameter values  $m$  and  $H_2$  for 2,407 participants in **Extended Data Fig 5C**, and the best-fit  
499 antibody titer curves of 600 randomly selected individuals are plotted along with the observed  
500 data for visualization in **Supplementary Fig 2**.

501

## 502 **Unsupervised clustering and stratification of antibody dynamics**

503 Unsupervised random forest clustering was performed on the selected features of the  
504 vaccine-elicited time-course antibody dynamics (rfUtilities package in R). After a random forest  
505 dissimilarity (i.e., the distance matrix between all pairs of samples) was obtained, it was visualized

506 with Uniform Manifold Approximation and Projection (UMAP) in a two-dimensional plane and was  
507 stratified with spectral clustering (Python scikit-learn). The optimal number of clusters was  
508 determined by the eigengap heuristic method.

509

### 510 **Random forest classifiers for characterizing stratified groups**

511 Random forest classifiers were trained to predict either of the six stratified groups (G1-  
512 G6) or their combination (G1/G2, G5/G6) using randomForest and rfPermute packages in R. The  
513 receiver operating characteristic (ROC) curve for each classifier was drawn from out-of-bag  
514 (OOB) samples using the pROC package in R. Feature importance was based on  
515 MeanDecreaseAccuracy and was shown as Chord diagrams (circlize package in R). Only the  
516 features with  $p < 0.05$  (obtained with 1,000 permutations) were selected.

517

### 518 **Statistical analysis**

519 The paper-based questionnaires collected from 2,159 participants were converted into a  
520 set of categorical and numerical variables. Numerical variables included age and the interval  
521 between the two doses. These variables were then used as input features to random forest  
522 classifiers to predict each stratified group (G1-G6). Missing values of categorical variables were  
523 treated as a separate category and included in the analyses. The variables used here belonged  
524 to any of the following five categories: (i) basic demographic information and lifestyle habits, (ii)  
525 information on vaccinations, (iii) underlying medical conditions, (iv) adverse reactions, and (v)  
526 medications being taken. As a subanalysis, we also divided participants into three generations  
527 according to age (0-39 [young], 40-64 [middle-aged], and 65-100 [old]) and trained random forest  
528 classifiers in each generation. When necessary, the same variables were compared among  
529 different generations or different groups using Pearson's chi-square test (for categorical variables),  
530 analysis of variance (ANOVA, for more than two numerical variables), or Welch T-test (for two  
531 numerical variables). The Pearson correlation coefficient was calculated to evaluate the  
532 association between a pair of continuous variables. To calculate the correlation matrix between

533 features, we augmented the variables by adding the following three categories to the above five  
534 categories: (vi) antibody titers of each individual, (vii) dynamic parameters of each individual, and  
535 (viii) dummy variables specifying each stratified group (G1 to G6). The correlation matrix of these  
536 variables (features) was used as an input to principal component analysis. All statistical analyses  
537 were performed using R (version 4.1.2).

538 **LIST OF SUPPLEMENTARY MATERIALS**

539 **Supplementary Figure 1** | Sensitive analysis on different threshold of vaccine efficacy

540 **Supplementary Figure 2** | Antibody titer trajectory for individual participants stratified into  
541 different groups

542 **Supplementary Table 1** | Details of query words and results

543 **Supplementary Table 2** | Characteristic of previously reported cohorts

544 **Supplementary Table 3** | Characteristic of vulnerable population

545 **Supplementary Table 4** | Estimated fixed and individual parameters for 12 health care works

546 **Supplementary Note 1** | Literature review

547 **Supplementary Note 2** | Stratifying time-course pattern of antibody dynamics

548 **Supplementary Note 3** | Inter-relationship of various features

549

## 550 REFERENCES

- 551 1 Lumley, S. F. *et al.* Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care  
552 Workers. *N Engl J Med* **384**, 533-540, doi:10.1056/NEJMoa2034545 (2021).
- 553 2 Cromer, D. *et al.* Neutralising antibody titres as predictors of protection against SARS-CoV-2  
554 variants and the impact of boosting: a meta-analysis. *Lancet Microbe* **3**, e52-e61,  
555 doi:10.1016/S2666-5247(21)00267-6 (2022).
- 556 3 Khoury, D. S. *et al.* Neutralizing antibody levels are highly predictive of immune protection from  
557 symptomatic SARS-CoV-2 infection. *Nat Med* **27**, 1205-1211, doi:10.1038/s41591-021-01377-8  
558 (2021).
- 559 4 Pegu, A. *et al.* Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2  
560 variants. *Science* **373**, 1372-1377, doi:10.1126/science.abj4176 (2021).
- 561 5 Gaebler, C. *et al.* Evolution of antibody immunity to SARS-CoV-2. *Nature* **591**, 639-644,  
562 doi:10.1038/s41586-021-03207-w (2021).
- 563 6 Goldberg, Y. *et al.* Waning Immunity after the BNT162b2 Vaccine in Israel. *N Engl J Med* **385**,  
564 e85, doi:10.1056/NEJMoa2114228 (2021).
- 565 7 Khoury, J. *et al.* COVID-19 vaccine - Long term immune decline and breakthrough infections.  
566 *Vaccine* **39**, 6984-6989, doi:10.1016/j.vaccine.2021.10.038 (2021).
- 567 8 Levin, E. G. *et al.* Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6  
568 Months. *N Engl J Med* **385**, e84, doi:10.1056/NEJMoa2114583 (2021).
- 569 9 Wheatley, A. K. *et al.* Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-  
570 19. *Nat Commun* **12**, 1162, doi:10.1038/s41467-021-21444-5 (2021).
- 571 10 Cele, S. *et al.* Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization.  
572 *Nature* **602**, 654-656, doi:10.1038/s41586-021-04387-1 (2022).
- 573 11 Keehner, J. *et al.* Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System  
574 Workforce. *N Engl J Med* **385**, 1330-1332, doi:10.1056/NEJMc2112981 (2021).
- 575 12 Kotaki, R. *et al.* SARS-CoV-2 Omicron-neutralizing memory B-cells are elicited by two doses of  
576 BNT162b2 mRNA vaccine. *Sci Immunol*, eabn8590, doi:10.1126/sciimmunol.abn8590 (2022).
- 577 13 Perez-Then, E. *et al.* Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron  
578 variants following heterologous CoronaVac plus BNT162b2 booster vaccination. *Nat Med* **28**,  
579 481-485, doi:10.1038/s41591-022-01705-6 (2022).
- 580 14 Falsey, A. R. *et al.* SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. *N Engl J Med*  
581 **385**, 1627-1629, doi:10.1056/NEJMc2113468 (2021).
- 582 15 Goel, R. R. *et al.* Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-  
583 CoV-2 mRNA vaccine. *bioRxiv*, doi:10.1101/2022.02.20.481163 (2022).
- 584 16 Muik, A. *et al.* Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited  
585 human sera. *Science* **375**, 678-680, doi:10.1126/science.abn7591 (2022).
- 586 17 Xia, H. *et al.* Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against  
587 Omicron SARS-CoV-2. *Cell Host Microbe*, doi:10.1016/j.chom.2022.02.015 (2022).
- 588 18 Choi, A. *et al.* Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in  
589 healthy adults: an interim analysis. *Nat Med* **27**, 2025-2031, doi:10.1038/s41591-021-01527-y  
590 (2021).
- 591 19 Juno, J. A. & Wheatley, A. K. Boosting immunity to COVID-19 vaccines. *Nat Med* **27**, 1874-  
592 1875, doi:10.1038/s41591-021-01560-x (2021).
- 593 20 Shroff, R. T. *et al.* Immune responses to two and three doses of the BNT162b2 mRNA vaccine in  
594 adults with solid tumors. *Nat Med* **27**, 2002-2011, doi:10.1038/s41591-021-01542-z (2021).
- 595 21 Wei, J. *et al.* Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general  
596 population of the United Kingdom. *Nat Microbiol* **6**, 1140-1149, doi:10.1038/s41564-021-00947-  
597 3 (2021).
- 598 22 Lustig, Y. *et al.* BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and  
599 dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. *Lancet*  
600 *Respir Med* **9**, 999-1009, doi:10.1016/S2213-2600(21)00220-4 (2021).

- 601 23 Kobashi, Y. *et al.* Seroprevalence of SARS-CoV-2 antibodies among hospital staff in rural Central  
602 Fukushima, Japan: A historical cohort study. *Int Immunopharmacol* **98**, 107884,  
603 doi:10.1016/j.intimp.2021.107884 (2021).
- 604 24 Kobashi, Y. *et al.* The difference between IgM and IgG antibody prevalence in different  
605 serological assays for COVID-19; lessons from the examination of healthcare workers. *Int*  
606 *Immunopharmacol* **92**, 107360, doi:10.1016/j.intimp.2020.107360 (2021).
- 607 25 Nakano, Y. *et al.* Time course of the sensitivity and specificity of anti-SARS-CoV-2 IgM and IgG  
608 antibodies for symptomatic COVID-19 in Japan. *Sci Rep* **11**, 2776, doi:10.1038/s41598-021-  
609 82428-5 (2021).
- 610 26 *Quantitative IgG antibodies to Spike protein of SARS-CoV-2*,  
611 <[https://icahn.mssm.edu/files/ISMMS/Assets/Departments/Pathology/COVQI\\_Link-to-Test-](https://icahn.mssm.edu/files/ISMMS/Assets/Departments/Pathology/COVQI_Link-to-Test-Information-and-Interpretation.pdf)  
612 [Information-and-Interpretation.pdf](https://icahn.mssm.edu/files/ISMMS/Assets/Departments/Pathology/COVQI_Link-to-Test-Information-and-Interpretation.pdf)> (2020).
- 613 27 Lucas, C. *et al.* Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity.  
614 *Nature* **600**, 523-529, doi:10.1038/s41586-021-04085-y (2021).
- 615 28 *Population Estimates by Age (Five-Year Groups) and Sex - July 1, 2021*,  
616 <<https://www.stat.go.jp/data/jinsui/pdf/202112.pdf>> (2021).
- 617 29 Ward, H. *et al.* Population antibody responses following COVID-19 vaccination in 212,102  
618 individuals. *Nat Commun* **13**, 907, doi:10.1038/s41467-022-28527-x (2022).
- 619 30 Yau, K. *et al.* Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in  
620 Patients Undergoing Hemodialysis. *JAMA Netw Open* **4**, e2123622,  
621 doi:10.1001/jamanetworkopen.2021.23622 (2021).
- 622 31 Moyon, Q. *et al.* BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-  
623 2 variants in systemic lupus erythematosus. *Ann Rheum Dis* **81**, 575-583,  
624 doi:10.1136/annrheumdis-2021-221097 (2022).
- 625 32 Shroff, R. T. *et al.* Immune responses to two and three doses of the BNT162b2 mRNA vaccine in  
626 adults with solid tumors. *Nat Med* **27**, 2002-2011, doi:10.1038/s41591-021-01542-z (2021).
- 627 33 Goel, R. R. *et al.* mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants  
628 of concern. *Science* **374**, abm0829, doi:10.1126/science.abm0829 (2021).
- 629 34 Feng, S. *et al.* Correlates of protection against symptomatic and asymptomatic SARS-CoV-2  
630 infection. *Nat Med* **27**, 2032-2040, doi:10.1038/s41591-021-01540-1 (2021).
- 631 35 Costiniuk, C. T. *et al.* CTN 328: immunogenicity outcomes in people living with HIV in Canada  
632 following vaccination for COVID-19 (HIV-COV): protocol for an observational cohort study.  
633 *BMJ Open* **11**, e054208, doi:10.1136/bmjopen-2021-054208 (2021).
- 634 36 Di Noia, V. *et al.* Rapid decline of humoral response to two doses of BNT162b2 vaccine in  
635 patients with solid cancer after six months: The urgent need of the additional dose! *Eur J Cancer*  
636 **165**, 169-173, doi:10.1016/j.ejca.2022.01.011 (2022).
- 637 37 Fenioux, C. *et al.* SARS-CoV-2 Antibody Response to 2 or 3 Doses of the BNT162b2 Vaccine in  
638 Patients Treated With Anticancer Agents. *JAMA Oncol*, doi:10.1001/jamaoncol.2021.7777  
639 (2022).
- 640 38 Ramasamy, M. N. *et al.* Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered  
641 in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised,  
642 controlled, phase 2/3 trial. *Lancet* **396**, 1979-1993, doi:10.1016/s0140-6736(20)32466-1 (2021).
- 643 39 Juno, J. A. *et al.* Humoral and circulating follicular helper T cell responses in recovered patients  
644 with COVID-19. *Nat Med* **26**, 1428-1434, doi:10.1038/s41591-020-0995-0 (2020).
- 645 40 Turner, J. S. *et al.* SARS-CoV-2 mRNA vaccines induce persistent human germinal centre  
646 responses. *Nature* **596**, 109-113, doi:10.1038/s41586-021-03738-2 (2021).
- 647 41 Turner, J. S. *et al.* SARS-CoV-2 infection induces long-lived bone marrow plasma cells in  
648 humans. *Nature* **595**, 421-425, doi:10.1038/s41586-021-03647-4 (2021).
- 649 42 Kim, W. *et al.* Germinal centre-driven maturation of B cell response to mRNA vaccination.  
650 *Nature* **604**, 141-145, doi:10.1038/s41586-022-04527-1 (2022).
- 651 43 Burki, T. K. Fourth dose of COVID-19 vaccines in Israel. *Lancet Respir Med* **10**, e19,  
652 doi:10.1016/S2213-2600(22)00010-8 (2022).

- 653 44 Abbasi, J. Fourth COVID-19 Vaccine Dose Increases Low Antibodies. *JAMA* **327**, 517,  
654 doi:10.1001/jama.2022.0727 (2022).
- 655 45 Anand, P. & Stahel, V. P. Correction to: The safety of Covid-19 mRNA vaccines: a review.  
656 *Patient Saf Surg* **15**, 22, doi:10.1186/s13037-021-00296-4 (2021).
- 657 46 Lin, D. Y. *et al.* Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina. *N*  
658 *Engl J Med* **386**, 933-941, doi:10.1056/NEJMoa2117128 (2022).
- 659 47 Traynard, P., Ayrat, G., Twarogowska, M. & Chauvin, J. Efficient Pharmacokinetic Modeling  
660 Workflow With the MonolixSuite: A Case Study of Remifentanyl. *CPT Pharmacometrics Syst*  
661 *Pharmacol* **9**, 198-210, doi:10.1002/psp4.12500 (2020).
- 662 48 *April 2021 Survey Population and Households by Municipality (Japanese Residents + Foreign*  
663 *Residents) (Japanese)*, <<https://www.kokudo.or.jp/service/data/map/fukushima.pdf>> (2021).
- 664 49 *The incidence of COVID-19 in Fukushima Prefecture (Japanese)*,  
665 <<https://www.pref.fukushima.lg.jp/sec/21045c/fukushima-hasseijyoukyou.html>> (2021).  
666  
667

## 668 **ACKNOWLEDGMENTS**

669 We would like to thank all the staff from Fukushima Medical University, Seireikai health  
670 care group, Hirata village office, Soma City office, Soma Central Hospital, Soma General Hospital,  
671 Minamisoma City office, Minamisoma City Medical Association, Minamisoma Municipal General  
672 Hospital, Shindo Clinic and Medical Governance Institute, who contributed significantly to the  
673 accomplishment of this research, especially, Ms. Yuka Harada, Ms. Serina Noji, Ms. Naomi Ito,  
674 Dr. Makoto Kosaka, Mr. Anju Murayama, Mr. Sota Sugiura, Mr. Manato Tanaka, Ms. Yuna Uchi,  
675 Mr. Yudai Kaneda, Mr. Masahiko Nihei, Mr. Hideo Sato, Ms. Rie Yanai, Ms. Yasuko Suzuki, Ms.  
676 Keiko Abe, Dr. Hidekiyo Tachiya, Mr. Kouki Nakatsuka, Dr. Ryuzaburo Shineha, Ms. Miki Sato,  
677 Dr. Masahiko Sato, Mr. Naoharu Tadano, Mr. Kazuo Momma, Mr. Shu-ichi Mori, Ms. Saori  
678 Yoshisato, Ms. Katsuko Onoda, Mr. Satoshi Kowata, Mr. Masatsugu Tanaki, Dr. Tomoyoshi  
679 Oikawa, Dr. Joji Shindo, Ms. Xujin Zhu, Ms. Asaka Saito, Ms. Yuumi Kondo, and Ms. Tomoyo  
680 Nishimura. This study was supported by Medical & Biological Laboratories Co., Ltd., Shenzhen  
681 YHLO Biotech Co., Ltd., the distributor and manufacturer of the antibody measurement system  
682 (iFlash 3000), Research Center for Advanced Science and Technology in the University of Tokyo,  
683 and in part by a National Research Foundation of Korea (NRF) grant funded by the Korea  
684 government (MSIT) (2022R1C1C2003637) (to K.S.K.); a Grant-in-Aid for JSPS Scientific  
685 Research (KAKENHI) B 18H01139 (to S.I.), 16H04845 (to S.I.), Scientific Research in Innovative  
686 Areas 20H05042 (to S.I.); AMED CREST 19gm1310002 (to S.I.); AMED Development of  
687 Vaccines for the Novel Coronavirus Disease, 21nf0101638s0201 (to S.I.), 21nf0101638h0001 (to  
688 M.T.); AMED Japan Program for Infectious Diseases Research and Infrastructure,  
689 20wm0325007h0001 (to S.I.), 20wm0325004s0201 (to S.I.), 20wm0325012s0301 (to S.I.),  
690 20wm0325015s0301 (to S.I.); AMED Research Program on HIV/AIDS 22fk0410052s0401 (to  
691 S.I.); AMED Research Program on Emerging and Re-emerging Infectious Diseases  
692 20fk0108140s0801 (to S.I.); AMED Program for Basic and Clinical Research on Hepatitis  
693 21fk0210094 (to S.I.); AMED Program on the Innovative Development and the Application of New  
694 Drugs for Hepatitis B 22fk0310504h0501 (to S.I.); AMED Strategic Research Program for Brain



695 Sciences 22wm0425011s0302; AMED JP22dm0307009 (to K.A.); JST MIRAI JPMJMI22G1 (to  
696 S.I.); Moonshot R&D JPMJMS2021 (to K.A. and S.I.) and JPMJMS2025 (to S.I.); Institute of AI  
697 and Beyond at the University of Tokyo (to K.A.); Mitsui Life Social Welfare Foundation (to S.I.);  
698 Shin-Nihon of Advanced Medical Research (to S.I.); Suzuken Memorial Foundation (to S.I.); Life  
699 Science Foundation of Japan (to S.I.); SECOM Science and Technology Foundation (to S.I.); The  
700 Japan Prize Foundation (to S.I.); Foundation of Kinoshita Memorial Enterprise (to S.I.); and Kowa  
701 Co (to M.T.).

702

## 703 **AUTHOR CONTRIBUTIONS**

704 SI and MT designed the research. YKobashi, YS, TZ, YN, FO, MTa, CY, KS, and MTs  
705 conducted the data collection and curation. YT, MK, MY, TA, YS, SN, TK, AS, AN, YS and  
706 YKaneko carried out the investigations. NN, KSK, DT, MA, Siwanami, KA, and SI carried out the  
707 computational analysis. SI and MT supervised the project. All authors contributed to writing the  
708 manuscript.

709

## 710 **COMPETING FINANCIAL INTERESTS**

711 YKaneko is employed by Medical & Biological Laboratories, Co. (MBL, Tokyo, Japan).  
712 MBL imported the testing material used in this research. YKaneko participated in the testing  
713 process; however, he did not engage in the research design and analysis. YKobashi and MT  
714 received a research grant from Pfizer Health Research Foundation for research not associated  
715 with this work.

716

## 717 **INSTITUTIONAL REVIEW BOARD STATEMENT**

718 This study was approved by the ethics committees of Hirata Central Hospital (number  
719 2021-0611-1) and Fukushima Medical University (number 2021-116). This study was conducted  
720 in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki).


721

722 **INFORMED CONSENT STATEMENT**


723 Informed consent was obtained from all subjects involved in the study.

724


725 **EXTENDED DATA FIGURES**




726 **Extended Data Figure 1 | Comparison between IgG(S) and neutralization activity: (A)** Curve  
727 with IgG(S) and neutralization activity on the Y-axis and its corresponding neutralization activity  
728 rank on the X-axis are plotted in black and gray, respectively. **(B)** Correlations between IgG(S)  
729 and neutralization activity from same samples are described. Data points represent individual  
730 samples. Correlations were calculated as Pearson correlation coefficients.




731 **Extended Data Figure 2 | Clustering vaccine-elicited antibody response: (A)** UMAP of 10  
 732 clustered antibody responses based on the extracted features from the reconstructed individual-  
 733 level antibody dynamics are shown. Data points represent individual participants and are colored  
 734 by the 10 clusters (i.e., C1 to C10). **(B)** Reconstructed individual antibody dynamics after 25 days  
 735 after the first vaccination in each cluster in the different colors are represented along with the  
 736 measured IgG(S). The black and red circles correspond to individuals who had 2 or 3  
 737 measurements of antibody titers at different time points, respectively. **(C)** The difference in  
 738 antibody titers between the two measurements and its sampling interval are compared among  
 739 clusters. **(D)** Reconstructed individual antibody dynamics after 25 days after the first vaccination  
 740 in each group in the different colors are represented along with the measured IgG(S) in black and  
 741 red corresponding to individuals who had 2 or 3 measurements, respectively. The red curves  
 742 indicate individuals who were infected with SARS-CoV-2 or whose family was infected. The  
 743 horizontal dashed lines correspond to 200 and 10 AU/mL, respectively.



744 **Extended Data Figure 3 | Characterization of stratification: (A) and (B)** The ROC curves of  
 745 random forest classifiers trained on predicting G3, G4, or G5/G6 in young, middle-aged, and old  
 746 populations are shown, respectively. The corresponding AUC value of each ROC curve is  
 747 calculated on the top of each panel. **(C)** Name labels of **Figure 3D** (principal component analysis  
 748 of features) are shown.



749 **Extended Data Figure 4 | Simulating booster vaccines under different scenarios: (A)**  
 750 Predicted individual elicited antibody responses in each group over the first year after the booster  
 751 vaccination at 1 year after the first vaccination are shown. The horizontal dashed and vertical  
 752 dotted lines correspond to 200 and 10 AU/mL and at 180 and 240 days after the first vaccination,  
 753 respectively. **(B)** and **(C)** show the fractions of individuals with antibody titers above 200 and  
 754 AU/mL with (i.e., colored curves) and without (i.e., black dashed curve) 100% booster vaccination  
 755 at 240 and 365 days after the first vaccination, respectively. **(D)** and **(E)** show those above 200  
 756 and 10 AU/mL with and without 50% booster vaccination at 240 days after the first vaccination,  
 757 respectively. The green, blue, and red curves correspond to the booster vaccination targeting  
 758 individuals randomly sampled from “in addition G1/G2, extra are from G1-G6”, “G1-G6”, and “in  
 759 addition G5/G6, extra are from G1-G6”, respectively.



760 **Extended Data Figure 5 | Quantification of vaccine-elicited antibody dynamics: (A)**  
 761 **Schematic diagram of mathematical modeling. (B) Observed and fitted IgG(S) titers for individual**  
 762 **participants are described. The IgG(S) titers are obtained from the 12 health care workers with**  
 763 **sequentially sampled serum for 40 days (on average 25 samples per individual). Enlarged view**  
 764 **of the dotted box shows a fine-level plot focusing on the early period. The dashed vertical lines at**  
 765 **day 21 correspond to the date of second vaccination. (C) Distributions of estimated parameter**  
 766 **values of  $H_2$  and  $m$  for 2,407 participants are plotted, among total or stratified**  
 767 **populations. (D) Distributions of the extracted features from the reconstructed individual-level**  
 768 **antibody dynamics are plotted, respectively, among total or stratified populations.**

## Extended Data Table 1 | Basic demographics for the Fukushima vaccination cohort

Characteristic	<40 years	40-64 years	>65 years	Overall	p-value
<b>Gender</b>					0.001
Male	338(46.8)	421(38.2)	286(40.8)	1045(41.4)	
<b>Vaccine type</b>					0.015
BNT162b2(Pfizer–BioNTech)	651(90.0)	971(88.1)	649(92.6)	2271(89.9)	
mRNA-1273(Moderna)	0(0.0)	3(0.3)	0(0.0)	3(0.1)	
<b>Days (mean [SD])</b>					
from 1st dose	106.3[37.7]	104.4[35.1]	103.8[17.2]	104.8[32.0]	0.302
from 2nd dose	181.4[37.5]	180.1[35.7]	180.1[16.9]	180.5[32.2]	0.292
<b>Blood type</b>					
A	239(35.7)	427(39.0)	212(35.4)	878(37.2)	<0.001
B	151(22.6)	236(21.6)	140(23.4)	527(22.3)	<0.001
O	213(31.8)	326(29.8)	172(28.7)	711(30.1)	0.367
AB	66(9.9)	105(9.6)	75(12.5)	246(10.4)	0.432
<b>BCG history</b>	560(83.5)	907(83.1)	412(61.9)	1879(77.4)	0.395
<b>Smoking</b>	144(19.9)	253(23.0)	63(9.0)	460(18.2)	<0.001
<b>Drinking habits</b>					<0.001
Almost not	403(55.7)	542(49.2)	458(65.3)	1403(55.5)	
Occasionally	247(34.2)	310(28.1)	90(12.8)	647(25.6)	
Everyday	63(8.7)	222(20.2)	127(18.1)	412(16.3)	
<b>Daily Alcohol Consumption</b>					<0.001
<20g	322(44.5)	382(34.7)	176(25.1)	880(34.8)	
20-40g	108(14.9)	214(19.4)	87(12.4)	409(16.2)	
40-60g	20(2.8)	60(5.4)	20(2.9)	100(4.0)	
>60g	5(0.7)	13(1.2)	2(0.3)	20(0.8)	
<b>Comorbidities</b>					
Hypertension	8(1.1)	237(21.5)	432(61.6)	677(26.8)	<0.001
Dyslipidemia	12(1.7)	123(11.2)	146(20.8)	281(11.1)	<0.001
Heart disease	14(1.9)	47(4.3)	140(20.0)	201(8.0)	<0.001
Diabetes	6(0.8)	72(6.5)	110(15.7)	188(7.4)	<0.001
Allergic disease	69(9.5)	95(8.6)	21(3.0)	185(7.3)	<0.001
Asthma	49(6.8)	45(4.1)	28(4.0)	122(4.8)	0.079
Liver disease	11(1.5)	45(4.1)	58(8.3)	114(4.5)	<0.001
Cancer	3(0.4)	35(3.2)	46(6.6)	84(3.3)	<0.001
Gout	5(0.7)	45(4.1)	26(3.7)	76(3.0)	0.001
Thyroid disease	8(1.1)	40(3.6)	11(1.6)	59(2.3)	0.005
Lung disease	12(1.7)	11(1.0)	28(4.0)	51(2.0)	<0.001
Mental disease	17(2.4)	16(1.5)	13(1.9)	46(1.8)	0.739
Rheumatism	2(0.3)	16(1.5)	19(2.7)	37(1.5)	0.006
Kidney disease	6(0.8)	7(0.6)	14(2.0)	27(1.1)	0.089
Anaphylaxis	6(0.8)	7(0.6)	5(0.7)	18(0.7)	0.994
Collagen disease	4(0.6)	6(0.5)	5(0.7)	15(0.6)	0.993
COVID-19 (family)	4(0.6)	5(0.5)	1(0.1)	10(0.4)	0.793
COVID-19	0(0.0)	3(0.3)	4(0.6)	7(0.3)	0.38
Immune deficiency	2(0.3)	4(0.4)	0(0.0)	6(0.2)	0.654
Others	51(7.1)	147(13.3)	189(27.0)	387(15.3)	<0.001
<b>Drug</b>					
Steroid	9(1.2)	23(2.1)	26(3.7)	58(2.3)	0.002
NSAIDs	31(4.3)	78(7.1)	82(11.7)	191(7.6)	<0.001
Acetaminophen	8(1.1)	22(2.0)	30(4.3)	60(2.4)	<0.001
Antihistamine	46(6.4)	65(5.9)	43(6.1)	154(6.1)	0.367
Immunosuppressants	6(0.8)	10(0.9)	8(1.1)	24(1.0)	0.432



Biologics	2(0.3)	5(0.5)	4(0.6)	11(0.4)	0.395
Anti-cancer agent	0(0.0)	5(0.5)	5(0.7)	10(0.4)	0.292
<b>Adverse Reaction</b>					
Local pain	515(71.2)	684(62.1)	228(32.5)	1427(56.5)	<0.001
Fatigue	511(70.7)	627(56.9)	119(17.0)	1257(49.8)	<0.001
Joint pain	327(45.2)	354(32.1)	90(2.8)	771(30.5)	<0.001
Fever (over 37.5 degree)	370(51.2)	308(28.0)	41(5.9)	719(28.5)	<0.001
Headache	321(44.4)	331(30.0)	34(4.9)	686(27.2)	<0.001
Fever (under 37.5 degree)	137(19.0)	209(19.0)	40(5.7)	386(15.3)	<0.001
Dizziness	57(7.9)	45(4.1)	9(1.3)	111(4.4)	<0.001
Nausea	51(7.1)	41(3.7)	6(0.9)	98(3.9)	<0.001
Diarrhea	30(4.2)	25(2.3)	3(0.4)	58(2.3)	<0.001
Others	40(5.5)	69(6.3)	16(2.3)	125(5.0)	0.003


770

## Supplementary Information



Stratifying elicited antibody dynamics after two doses of SARS-CoV-2 vaccine in a community-based cohort in Fukushima, Japan

Naotoshi Nakamura<sup>1,†</sup>, Yurie Kobashi<sup>2,3,†</sup>, Kwang Su Kim<sup>1,4,5,†</sup>, Yuta Tani<sup>6</sup>, Yuzo Shimazu<sup>2</sup>, Tianchen Zhao<sup>2</sup>, Yoshitaka Nishikawa<sup>3</sup>, Fumiya Omata<sup>3</sup>, Moe Kawashima<sup>2</sup>, Makoto Yoshida<sup>6</sup>, Toshiki Abe<sup>2</sup>, Yoshika Saito<sup>6</sup>, Yuki Senoo<sup>6</sup>, Saori Nonaka<sup>2</sup>, Morihito Takita<sup>2</sup>, Chika Yamamoto<sup>2</sup>, Takeshi Kawamura<sup>7,8</sup>, Akira Sugiyama<sup>7</sup>, Aya Nakayama<sup>7</sup>, Yudai Kaneko<sup>8,9</sup>, Hyeongki Park<sup>1</sup>, Yong Dam Jeong<sup>1,5</sup>, Daiki Tatematsu<sup>1</sup>, Marwa Akao<sup>1</sup>, Yoshitaka Sato<sup>10</sup>, Shoya Iwanami<sup>1</sup>, Yasuhisa Fujita<sup>1</sup>, Masatoshi Wakui<sup>11</sup>, Kazuyuki Aihara<sup>12</sup>, Tatsuhiko Kodama<sup>8</sup>, Kenji Shibuya<sup>13,14</sup>, Shingo Iwami<sup>1,16,17,18,19,20,‡,\*</sup> and Masaharu Tsubokura<sup>2,3,6,20,‡</sup>

<sup>1</sup>interdisciplinary Biology Laboratory (iBLab), Division of Natural Science, Graduate School of Science, Nagoya University, Nagoya, Japan. <sup>2</sup>Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima, Japan. <sup>3</sup>Department of General Internal Medicine, Hirata Central Hospital, Fukushima, Japan. <sup>4</sup>Department of Science System Simulation, Pukyong National University, Busan, South Korea. <sup>5</sup>Department of Mathematics, Pusan National University, Busan, South Korea. <sup>6</sup>Medical Governance Research Institute, Tokyo, Japan. <sup>7</sup>Proteomics Laboratory, Isotope Science Center, The University of Tokyo, Tokyo, Japan. <sup>8</sup>Laboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan. <sup>9</sup>Medical & Biological Laboratories Co., Ltd, Tokyo, Japan. <sup>10</sup>Department of Virology, Nagoya University Graduate School of Medicine, Nagoya, Japan. <sup>11</sup>Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan. <sup>12</sup>International Research Center for Neurointelligence, The University of Tokyo Institutes for Advanced Study, The University of Tokyo, Tokyo, Japan. <sup>13</sup>Soma Medical Center of vaccination for COVID-19, Fukushima, Japan. <sup>14</sup>Tokyo Foundation for Policy Research, Tokyo, Japan. <sup>15</sup>Institute of Mathematics for Industry, Kyushu University, Fukuoka, Japan. <sup>16</sup>Institute for the Advanced Study of Human Biology (ASHBi), Kyoto University, Kyoto, Japan. <sup>17</sup>Interdisciplinary Theoretical and Mathematical Sciences Program (iTHEMS), RIKEN, Saitama, Japan. <sup>18</sup>NEXT-Ganken Program, Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan. <sup>19</sup>Science Groove Inc., Fukuoka, Japan. <sup>20</sup>Minamisoma Municipal General Hospital, Fukushima, Japan.



**Supplementary Figure 1. Sensitivity analysis on different thresholds of vaccine efficacy: (A) and (B) show the fractions of individuals with antibody titers of  $<10$ ,  $10-80$ , and  $80 < \text{AU/mL}$  in each group at 180, 240, and 365 days after the first vaccination and at 1 month post-booster vaccination plotted as black, white, and group color, respectively (for 200 AU/mL, corresponding to **Fig 2H** and **Fig 4B**). (C), (D), and (E) represent the time-dependent fractions of individuals with antibody titers above 80 AU/mL with (i.e., colored curves) and without (i.e., black dashed curve) 100%, 50%, and 20% booster vaccination at 240 days (and 365 days for 100% booster vaccination) after the first vaccination, respectively, similar to **Extended Data Fig 4B**, **Fig 4D** and **Extended Data Fig 4D** for 200 AU/mL of the threshold.**



Days after 1<sup>st</sup> vaccination

IgG (S) (AU/mL)



**Supplementary Figure 2. Antibody titer trajectory for individual participants stratified into different groups:** The estimated antibody titer for each individual participant (solid lines) along with the observed data (closed dots) are depicted using the best-fit parameter estimates. G1, G2, G3, G4, G5, and G6 are shown in yellow, gray, green, light blue, blue, and pink, respectively. In each group, the curve of 100 was randomly selected for visualization because of the large number.

**Supplementary Table 1.** Details of query words and results of the literature review

#	Query Word	Results
1	"SARS-CoV-2" [tiab] OR "severe coronavirus disease 2019" [tiab] OR "COVID-19" [tiab] OR "severe acute respiratory syndrome coronavirus 2" [tiab] OR "coronavirus disease 2019" [tiab] OR "COVID-19*" [Mesh] OR "SARS-CoV-2**"	235,156
2	"vaccination*" [tiab] OR "vaccine*" [tiab] OR "NVX-CoV2373" [tiab] OR "CVnCoV" [tiab] OR "Ad26COV2S" [tiab] OR "BNT162 Vaccine*" [Mesh] OR "ChAdOx1 nCoV-19" [Mesh] OR "COVID-19 Vaccines*" [Mesh] OR "mRNA Vaccines" [Mesh] OR "RNA, Viral" [Mesh] OR "Vaccination*" [Mesh] OR "Vaccine Efficacy*" [Mesh] OR "Vaccines*" [Mesh] OR "2019-nCoV Vaccine mRNA-1273*" [Mesh] OR "Ad26COVS1" [Mesh]	500,257
3	"Antibody level*" [tiab] OR "antibody response*" [tiab] OR "Antibody titer*" [tiab] OR "Humoral and Cellular Response*" [tiab] OR "humoral immune response*" [tiab] OR "humoral response*" [tiab] OR "immune response*" [tiab] OR "immunization" [tiab] OR "immunogenicity" [tiab] OR "Antibodies, Viral" [Mesh] OR "Antibody Formation" [Mesh] OR "Immunity, Humoral*" [Mesh] OR "Immunogenicity, Vaccine*" [Mesh]	557,862
4	"Second dose" [tiab] OR "second SARS-CoV-2 vaccine" [tiab] OR "2nd dose" [tiab] OR "second vaccination" [tiab] OR "two doses" [tiab] OR "two sequential doses" [tiab] OR "Two Vaccine Doses" [tiab] OR "two-dose" [tiab] OR "booster doses" [tiab] OR "second vaccine" [tiab] OR "Immunization, Secondary*" [Mesh]	30,432
5	"Cohort" [tiab] OR "Cross-Sectional" [tiab] OR "Follow-Up Studies" [tiab] OR "Prospective Studies" [tiab] OR "Cohort Studies" [Mesh] OR "Cross-Sectional Studies" [Mesh] OR "Follow-Up Studies" [Mesh] OR "Prospective Studies" [Mesh] OR "Observational Study*" [tiab]	3,119,085
6	1 AND 2	32,087
7	1 AND 2 AND 3	7,561
8	1 AND 2 AND 3 AND 4	1,311
9	1 AND 2 AND 3 AND 4 AND 5	440

**Supplementary Table 2.** Characteristics of the previously reported cohorts

#	Cohort Size	Study Period	Country	Vaccine Type	Population Characteristics	Interview Sheet	Times of Sampling	Sample 1	Sample 2	Sample final	Number of Participants Included in All Sampling	Samples of Neutralizing Antibody	Sample1 of Neutralizing Antibody	Reference
0	2526	270	Japan	BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna)	Community	Including	2	2526	2443	2443	2443	Including	2526	This study
1	3,991	200	Israel	BNT162b2 (Pfizer–BioNTech)	HCWs	Including	7	3991	2690	1370	693	Including	681	1
2	2,591	180	Italy	BNT162b2 (Pfizer–BioNTech)	Community	Not Including	4	1725	1641	2591	1215	Not Including	NA	2
3	1,935	90	Italy	BNT162b2 (Pfizer–BioNTech)	HCWs	Not Including	3	1935	NA	NA	NA	Including	1935	3
4	1,506	90	Israel	BNT162b2 (Pfizer–BioNTech)	HCWs	Including	2	1506	1209	1209	1194	Not Including	NA	4
5	1,487	41	Israel	BNT162b2 (Pfizer–BioNTech)	HCWs	Including	5	334	375	1487	22	Including	46	5
6	1,012	102	Turkey	CoronaVac (Sinovac)	HCWs	Including	2	1012	836	836	836	Not Including	NA	6



**Supplementary Table 3. Characteristics of the vulnerable population**

#	Cohort Size	Vaccine Type	Country	Population Characteristics	Age	Sex	Obesity BMI>30	Immunosuppression	Steroid	Hypertension	Autoimmune disease	Heart disease	Lung disease	Kidney disease	Interval / Joint pain	Fever over 37.5	Other factors (P<0.05)	others factors (P>0.05)	Reference
1	3991	BNT162b2(Pfizer–BioNTech)	Israel	HCWs	+	+	+	+	NA	NA	+	NA	NA	NA	NA	NA	• the presence of two or more coexisting conditions (i.e., hypertension, diabetes, dyslipidemia, or heart, lung, kidney, or liver disease) • age-sex interaction	NA	1
2	1506	BNT162b2(Pfizer–BioNTech)	Israel	HCWs	+	+	NA	+	-	NA	NA	NA	NA	NA	NA	NA	• Underlying conditions (i.e., hypothyroidism, autoimmune disease, cardiac disease, lung disease, immunodeficiency, chronic renal disease, and active oncological disease)	• age-sex interaction • Allergic reactions	4
3	1487	BNT162b2(Pfizer–BioNTech)	Israel	HCWs	+	-	-	+	NA	-	-	-	±	NA	NA	NA	NA	• Diabetes	5
4	1012	CoronaVac(Sinovac)	Turkey	HCWs	+	+	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	6
5	632	BNT162b2(Pfizer–BioNTech)	Italy	Patients: cancer	-	+	+	+	+	NA	NA	NA	NA	NA	NA	NA	• Concomitant disease • Therapeutic setting • Active anticancer treatment	• ECOG PS • Number of metastatic sites • Type of Metastases	7
6	552	CoronaVac(Sinovac)	UK	Community	+	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	8
7	548	BNT162b2(Pfizer–BioNTech) or CoronaVac(Sinovac)	Turkey	HCWs	+	-	+	+	NA	NA	NA	NA	NA	NA	NA	NA	• occupation (Medical doctor, Nurse, other healthcare workers) • Presence of chronic disease (yes or no) • Pneumococcal vaccine (yes or no)	• smoking (Never,Current,Ever) • Vaccination status (influenza vaccine)	9
8	539	BNT162b2(Pfizer–BioNTech)	Sweden	Patients: primary immunodeficiency disorders (PID) or human immunodeficiency virus (HIV), HSCT/chimeric antigen receptor T (CAR T) cell therapy, solid organ transplantation (SOT), or chronic lymphocytic leukemia (CLL)	-	-	NA	-	NA	NA	NA	NA	NA	NA	NA	NA	• All immunocompromised patients • primary immunodeficiency • hematopoietic stem cell transplantation • solid organ transplantation • chronic lymphocytic leukemia • Patients groups (HIV vs PID, HSCT, SOT, CLL) • HSCT-subgroups (Late vs Early) • HSCT (GvHD absent vs severe) • SOT (Time to transplantation, Creatinine baseline, MMF) • SOT-type of organ (Liver vs Kidney) • CLL (IgG baseline) • CLL-subgroups (Indolent vs Ibrutinib)	• human immunodeficiency virus • Lymphocyte count at baseline • PID (Age, Sex, Co-morbidity, IgG at baseline, Autoimmunity, Malignancy) • PID-subgroup (COVID vs CD4 cytop., Monogenic disease, Other, XLA) • HSCT-subgroups (Late vs Intermediate) • HSCT (GvHD absent vs mild, moderate) • HSCT (Age, Sex, GvHD) • SOT-type of organ (Liver vs Kidney/pancreas) • SOT (Age, Sex, Tacrolimus) • CLL (Age, Sex) • CLL-subgroups (Indolent vs Off ibritinib, Previous CD20-mAb)	10
9	481	ChAdOx1 nCoV-19(AstraZeneca) or BBV-152(Bharat Biotech)	India	HCWs	+	-	-	NA	NA	+	NA	-	NA	NA	NA	NA	• Co-morbidities (No co-morbidities vs Any co-morbidities) • Vaccine type (Vocaxin vs Covaxin) • Previous infection	• Blood Group • Type2 Diabetes Mellitus (No vs Yes) • Duration of T2DM (<5years vs 5-10 years, >10years) • Dyslipidaemia • Ischemic Heart Disease	11
10	289	BNT162b2(Pfizer–BioNTech)	Israel	Patients: Dialysis	-	-	NA	NA	NA	NA	NA	NA	NA	+	NA	NA	• dialysis + Post COVID-19 Infection • Albumin	• hemodialysis • peritoneal dialysis Diabetes • Dialysis vintage (dialysis adequacy HD, dialysis adequacy PD)	12
11	276	BNT162b2(Pfizer–BioNTech) or ChAdOx1 nCoV-19(AstraZeneca)	Greece	Patients: monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma (SMM)	-	+	-	+	NA	NA	NA	NA	NA	NA	NA	NA	• Multiple myeloma • treatment type: anti-BCMA-based regimens (belantamab mafodotin and anti-CD38 monoclonal antibodies), anti-CD38-based regimens • lymphopenia • low levels of IgA	• MGUS, smoldering multiple myeloma • International Staging System: ISS (Stage 1 vs 2, 3) • Revised International Staging System: RISS (Stage 1 vs 2, 3) • Myeloma type (IgG vs IgA, IgM, KLC, LLC) • low levels of IgM, IgG • treatment type: PI/IMiD-based combinations, Lenalidomide maintenance	13

12	248	BNT162b2(Pfizer-BioNTech)	France	Patients: receiving ICI, patients with pneumonectomy or chronic radiation pneumonitis, patients on oral tyrosine kinase targeted therapy (tyrosine kinase inhibitors [TKIs]); and patients without systemic therapy	+	+	NA	+	+	NA	NA	NA	NA	NA	NA	NA	<ul style="list-style-type: none"> <li>chemotherapy, targeted therapy, bevacizumab</li> <li>without systemic therapy within 3 months</li> <li>single-agent ICI treatment within last 3 months</li> </ul>	<ul style="list-style-type: none"> <li>chemotherapy vs immunotherapy</li> </ul>	14
13	200	BNT162b2(Pfizer-BioNTech)	Japan	Patients: hemodialysis (HD)	+	-	-	NA	NA	+	NA	+	NA	NA	NA	NA	<ul style="list-style-type: none"> <li>History of stroke, Dementia</li> <li>White blood cell count</li> </ul>	<ul style="list-style-type: none"> <li>Creatinine</li> <li>Blood urea nitrogen</li> <li>Hemoglobin</li> <li>White blood cell count</li> <li>Mean KT/V</li> <li>Dialysis mellitus</li> </ul>	15
14	200	BNT162b2(Pfizer-BioNTech)	Denmark	Patients: solid organ transplant (SOT) recipients	+	-	-	±	NA	NA	NA	+	NA	NA	NA	NA	<ul style="list-style-type: none"> <li>Transplanted &lt;1 year before vaccination</li> <li>Immunosuppressive treatment (Corticosteroids)</li> <li>Type of organ transplanted (Liver vs Kidney, Lung)</li> <li>Comorbidities (Diabetes mellitus, De novo non-skin cancer)</li> </ul>	<ul style="list-style-type: none"> <li>Immunosuppressive (No antimetabolite vs Azathioprine, Mycophenolate)</li> <li>Immunosuppressive (Calcineurin inhibitor vs mTOR inhibitor)</li> <li>Comorbidities (Chronic pulmonary disease)</li> </ul>	16
15	194	BNT162b2(Pfizer-BioNTech) or mRNA-1273(Moderna)	Switzerland	Patients: allogeneic hematopoietic cell transplantation (allo-HCT) graft-versus-host disease (GVHD)	+	-	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	<ul style="list-style-type: none"> <li>IST</li> <li>underlying disease</li> <li>allo-HCT recipients</li> <li>preinfection</li> </ul>	<ul style="list-style-type: none"> <li>chronic GVHD</li> </ul>	17
16	185	CoronaVac(Sinovac)	Thailand	HCWs	+	-	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	<ul style="list-style-type: none"> <li>occupation</li> </ul>	18
17	156	BNT162b2(Pfizer-BioNTech)	Portugal	Patients: hemodialysis (HD)	+	-	-	-	-	-	NA	-	NA	+	NA	NA	<ul style="list-style-type: none"> <li>Leukemia</li> </ul>	<ul style="list-style-type: none"> <li>Laboratory parameters (Hemoglobin, Serum sIbumin, Ferritin, nPCR, CRP, 25(OH) D3)</li> <li>Comorbidities (Diabetes mellitus, Chronic liver disease, Rheumatic disease, Past Kidney transplant)</li> <li>Medication (Erythropoiesis-stimulating agent, Angiotensin-converting-enzyme inhibitor, Statins, Corticosteroid, Other immunosuppressor/immunomodulator, Tacrolimus, Non-steroidal anti-inflammatory drug, Antithrombotic, Anti-HBc positivity)</li> </ul>	19
18	155	CoronaVac(Sinovac)	Turkey	Patients: kidney transplant recipients (KTRs) and hemodialysis (HD)	+	NA	-	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	<ul style="list-style-type: none"> <li>Absolute lymphocyte count</li> <li>Neutrophil lymphocyte ratio</li> <li>25-OH-vitamin D3</li> </ul>	20
19	150	BNT162b2(Pfizer-BioNTech)	Netherlands	Patients: previously SARS-CoV-2-infected	-	±	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	<ul style="list-style-type: none"> <li>illness on set dating &gt;1 year before vaccination</li> <li>severe disease outcomes</li> </ul>	NA	21
20	142	BNT162b2(Pfizer-BioNTech)	Canada	Patients: receiving in-center hemodialysis	-	-	NA	NA	NA	NA	NA	NA	+	NA	NA	NA	NA	NA	22
21	136	BNT162b2(Pfizer-BioNTech)	France	Patients: rheumatic and musculoskeletal	-	-	NA	NA	-	NA	NA	NA	NA	NA	NA	NA	<ul style="list-style-type: none"> <li>Mycophenolate</li> <li>Methotrexate</li> </ul>	<ul style="list-style-type: none"> <li>At least one BILAG score ≥B</li> <li>C3, g/L</li> <li>dsDNA antibodies, IU/mL</li> <li>Detectable IFN-α</li> <li>Total</li> </ul>	23

				diseases (RMDs) and associated immunomodulatory treatments														serum IgA, g/L • Total serum IgM, g/L • Lymphocytes count, G/L • Hydroxychloroquine • Azathioprine • Belimumab • Other immunosuppressor	
22	136	BNT162b2(Pfizer-BioNTech) or CoronaVac(Sinovac) or ChAdOx1 nCoV-19(AstraZeneca) or Ad26.COV2.S(Janssen)	Portugal	HCWs	-	-	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	• Vaccine reactogenicity	24
23	126	BNT162b2(Pfizer-BioNTech)	Germany	HCWs	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	• Selenium (Se) supplementation	25
24	110	BNT162b2(Pfizer-BioNTech) or ChAdOx1 nCoV-19(AstraZeneca) or mRNA-1273(Moderna)	France	HCWs	+	-	-	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	• Comorbidity	26
25	109	BNT162b2(Pfizer-BioNTech)	Finland	Patients: multiple myeloma (MM) and myeloproliferative malignancies (MPM)	-	-	-	+	NA	NA	NA	NA	NA	NA	NA	NA	• multiple myeloma (MM) • myeloproliferative malignancies (MPM) • Treatment (Daratumumab-based vs PI-based/Imids-based alone or in combo without daratumumab)	• Lines of therapy • Lymphocyte count • Time from diagnosis to vaccination	27
26	103	BNT162b2(Pfizer-BioNTech)	U.S.	Patients: solid tumors	NA	NA	NA	-	NA	NA	NA	NA	NA	NA	NA	NA	• cancer	NA	28
27	100	CoronaVac(Sinovac)	China	HCWs	+	-	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	• interval between two doses	NA	29
28	75	BBIBP-CorV(Sinopharm)	China	community	+	NA	+	NA	NA	NA	NA	NA	NA	NA	NA	NA	• absolute lymphocyte count • high levels of serum SAA (serum amyloid A) • low T3 before vaccination • Higher levels of absolute lymphocyte count accompanied by lower serum SAA	• biochemical routine indexes (blood cell counts and differentials,ALT,AST,GGT,CHE,ALP,TBA,LDH,CRP) • thyroid function markers except T3 • comorbidities	30
29	49	BNT162b2(Pfizer-BioNTech)	Japan	HCWs	+	-	NA	NA	NA	NA	NA	NA	NA	NA	NA	+	• alcohol drinking habits	• Smoking habits • Allergies • Other side effects after vaccination	31
30	44	BNT162b2(Pfizer-BioNTech)	Italy	Patients: chemotherapy	+	NA	±	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	• oncology(After 1 months) • Comorbidity • Progressive disease • Chemotherapy in progress • FIGO stage	32
31	43	BNT162b2(Pfizer-BioNTech)	Germany	Patients: dialysis	NA	NA	NA	NA	NA	NA	NA	NA	+	NA	NA	NA	• oncology(After 3 months)	NA	33
32	41	BNT162b2(Pfizer-BioNTech)	Japan	Patients: solid tumors	NA	NA	NA	+	NA	NA	NA	NA	NA	NA	NA	NA	• cytotoxic chemotherapy • immune checkpoint inhibitors	• cytotoxic chemotherapy vs immune checkpoint inhibitors	34
33	40	BNT162b2(Pfizer-BioNTech) or mRNA-1273(Moderna)	U.S.	HCWs	NA	-	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	• Previous infection	NA	35
34	29	BNT162b2(Pfizer-BioNTech)	Israel	Patients: primary brain tumors	-	+	NA	NA	+	NA	NA	NA	NA	NA	NA	NA	• primary brain tumors (PBTs)	• Treatments (Surgery, Temozolomide, Elapsed time from vaccination) • Diagnosis(Artypical meningioma, Glioblastoma multiforme, Oligodendroglioma)	37

**Supplementary Table 4.** Estimated fixed and individual parameters for 12 health care workers

<b>Parameter or variable</b>	Decay rate of antibody-secreting cells	Maximum <i>de novo</i> production of antibody by 1 <sup>st</sup> vaccination	Delay of antibody-secreting cells induction after 1 <sup>st</sup> vaccination.	Steepness at which induction increases with increasing the amount of mRNA	Amount of mRNA satisfying $P_i/2$	Maximum <i>de novo</i> production of antibody by 2 <sup>nd</sup> vaccination	Delay of antibody-secreting cells induction after 2 <sup>nd</sup> vaccination.
<b>Symbol</b>	$\mu$	$H_1$	$\eta_1$	$m$	$K$	$H_2$	$\eta_2$
<b>Unit</b>	day <sup>-1</sup>	AU/mL	day	---	$\mu\text{g}/0.5\text{mL}$	AU/mL	day
<b>Individual estimated parameters for <math>S_1</math> to <math>S_{12}</math></b>							
$S_1$	0.885346	650.518	12.5269	0.0373144	33900	5227.34	4.21433
$S_2$	0.885346	760.114	12.5109	0.028673	33900	5035.79	4.23423
$S_3$	0.885346	2375.11	12.5096	0.0223842	33900	7562.82	3.85759
$S_4$	0.885346	790.745	12.4927	0.0611514	33900	7304.66	3.95306
$S_5$	0.885346	942.686	12.5169	0.0250174	33900	5638.12	3.91276
$S_6$	0.885346	448.87	12.5243	0.0851651	33900	3828.1	4.24752
$S_7$	0.885346	1848.01	12.5471	0.0272096	33900	9073.94	4.2513
$S_8$	0.885346	567.839	12.5409	0.0523284	33900	4673.2	4.71178
$S_9$	0.885346	1835.9	12.5428	0.0365247	33900	7517.48	4.59114
$S_{10}$	0.885346	1201.77	12.5109	0.0625655	33900	5916.28	4.17894
$S_{11}$	0.885346	736.229	12.5086	0.0700219	33900	4118.67	4.54006
$S_{12}$	0.885346	1369.65	12.5409	0.0488345	33900	8226.08	4.23969
<b>Population estimated parameters</b>							
---	0.885346	975.297	12.52	0.0437653	33900	6035.142	4.25

## Supplementary Note 1: Literature review

This comprehensive literature review aimed to characterize the Fukushima vaccination cohort from previous cohort studies and to identify the factors contributing to the vulnerability of certain populations. A total of 440 articles published up to March 23, 2022, were collected using PubMed. Details of the search terms used in this analysis are provided in **Supplementary Table 1**. In the first step, a group of two or three authors (YT, MK, MY, TA, YS) screened and retrieved articles according to the following two criteria: (i) report evaluating antibody titer testing of human blood samples after two doses of SARS-CoV-2 vaccine; (ii) report collecting at least two blood samples after two doses of SARS-CoV-2 vaccine, and 92 articles met the criteria. **Fig 1F** shows the overall distribution of the cohort size and study period of the included papers. *Study period* was defined as the maximum period between the first vaccination and the completion of the last sampling, and *cohort size* was defined as the maximum number of participants who had at least one sample collected at certain sampling times during the period. The median cohort size was 103 and the median study period was 150 days, and six articles were found to have a cohort size of 1,000 or more (**Supplementary Table 2**). Next, we extracted and analyzed the factors contributing to vulnerable population status from 40 of 92 papers, including interview sheets, 6 of which were excluded because they did not analyze factors of vulnerability (**Supplementary Table 3**). From this literature review, we found that only the Fukushima cohort (1) consecutively sampled more than 2,000 of the same individuals with less dropout (only 3.3%); (2) included an interview sheet for all participants; (3) targeted “communities” (including non-HCWs); and (4) measured several modalities of antibody titers including neutralizing activity (**Supplementary Table 2**).

## Supplementary Note 2: Stratifying time-course pattern of antibody dynamics

For the purpose of stratification of the individual vaccine-elicited antibody response, we first applied unsupervised random forest clustering to the individual “reconstructed” antibody dynamics of 2,407 participants (e.g., **Supplementary Fig 2**) but failed to divide the time-course pattern of antibody dynamics into different clusters (data not shown). To overcome this problem, we employed an idea of “feature engineering”: extracting features to improve the quality of results from a machine-learning process, compared with supplying only the raw data to it. We quantified the peak, duration, and area under the curve of the reconstructed antibody dynamics as their features (**Extended Data Fig 5D**). Interestingly, the unsupervised random forest clustering based on these features in addition to our estimated individual parameters (i.e.,  $m$  and  $H_2$ ) identified 10 clusters that clearly discriminated the time-course patterns (**Extended Data Fig 2AB**). Since the time-course patterns of clusters 2, 3, 6, and 7 were similar and they were close together in two-dimensional Uniform Manifold Approximation and Projection (UMAP) embeddings (**Extended Data Fig 2A**), we merged these clusters into one group. In addition, we removed cluster 8 from further evaluation (i.e., we removed 245 individuals, around 10%, of the 2,407 participants in the Fukushima cohort) on the grounds that their reconstructed antibody dynamics with estimated parameters may not be reasonable. This is because their antibody titers measured from two blood samples showed statistically significantly small differences ( $p < 1.0 \times 10^{-16}$  by Welch two sample t-test) and their sampling intervals were significantly shorter than the others ( $p = 0.01$  by Welch two sample t-test) (**Extended Data Fig 2C**). This problem will be solved by adjusting for the timing of their blood sampling in our future study of booster vaccinations. Finally, we obtained 6 groups to evaluate the stratification in further detail (**Fig 2A**).

### Supplementary Note 3: Inter-relationship of various features

We visualized the inter-relationship of various features using principal component analysis (PCA) based on their correlation matrix (**Fig 3F** and **Extended Data Fig 3C**). We found that the first principal axis, explaining 25.9% of the variance, represents titers: the antibody titers and the dynamic parameters of each individual (i.e., their peak, duration, and area under the curve,  $m$  and  $H_2$ ) were located in the third quadrant of this PCA plane. The adverse events were in the second quadrant, suggesting their closeness to high antibody titers. However, most questionnaire items about basic demographic information and lifestyle habits remained in the middle, indicating their relatively minor role. A notable exception was age, which was inversely correlated with titers and was indeed situated in the fourth quadrant. By contrast, the second principal axis, explaining 9.8% of the variance, represents comorbidities and medication. Our stratification combines these information and places G1, G2, and G4 in the third quadrant; G3 in the middle; and G5 and G6 in the fourth quadrant near the comorbidities cluster and age.

## References

1. Levin, E.G., *et al.* Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. *N Engl J Med* **385**, e84 (2021).
2. Papadopoli, R., *et al.* Serological Response to SARS-CoV-2 Messenger RNA Vaccine: Real-World Evidence from Italian Adult Population. *Vaccines (Basel)* **9**(2021).
3. Buonfrate, D., *et al.* Antibody response induced by the BNT162b2 mRNA COVID-19 vaccine in a cohort of health-care workers, with or without prior SARS-CoV-2 infection: a prospective study. *Clin Microbiol Infect* **27**, 1845-1850 (2021).
4. Shachor-Meyouhas, Y., *et al.* Immunogenicity trends 1 and 3 months after second BNT162B2 vaccination among healthcare workers in Israel. *Clin Microbiol Infect* **28**, 450 e451-450 e454 (2022).
5. Lustig, Y., *et al.* BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. *Lancet Respir Med* **9**, 999-1009 (2021).
6. Demirbakan, H., Kocer, I., Erdogan, M. & Bayram, A. Assessing humoral immune response after two doses of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthcare workers. *Public Health* **205**, 1-5 (2022).
7. Di Noia, V., *et al.* Rapid decline of humoral response to two doses of BNT162b2 vaccine in patients with solid cancer after six months: The urgent need of the additional dose! *Eur J Cancer* **165**, 169-173 (2022).
8. Ramasamy, M.N., *et al.* Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. *Lancet* **396**, 1979-1993 (2021).
9. Caglayan, D., *et al.* An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey. *J Med Virol* **94**, 2212-2221 (2022).
10. Bergman, P., *et al.* Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. *EBioMedicine* **74**, 103705 (2021).
11. Singh, A.K., *et al.* Humoral antibody kinetics with ChAdOx1-nCOV (Covishield) and BBV-152 (Covaxin) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study. *Diabetes Metab Syndr* **16**, 102424 (2022).
12. Berar-Yanay, N., *et al.* Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients. *J Clin Med* **11**(2021).
13. Terpos, E., *et al.* The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. *Blood Cancer J* **11**, 138 (2021).
14. Gounant, V., *et al.* Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses. *J Thorac Oncol* **17**, 239-251 (2022).
15. Kitamura, M., *et al.* Low humoral immune response to the BNT162b2 vaccine against COVID-19 in nursing home residents undergoing hemodialysis: a case-control observational study. *Ren Replace Ther* **8**, 8 (2022).
16. Hamm, S.R., *et al.* Decline in Antibody Concentration 6 Months After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients and Healthy Controls. *Front Immunol* **13**, 832501 (2022).




17. Huang, A., *et al.* Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation. *Transplant Cell Ther* **28**, 214 e211-214 e211 (2022).
18. Benjamanukul, S., *et al.* Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers. *J Med Virol* **94**, 1442-1449 (2022).
19. Weigert, A., *et al.* Longitudinal Analysis of Antibody Responses to the mRNA BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis: A 6-Month Follow-Up. *Front Med (Lausanne)* **8**, 796676 (2021).
20. Dheir, H., *et al.* Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients. *J Med Virol* (2022).
21. van Gils, M.J., *et al.* A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern. *Cell Rep Med* **3**, 100486 (2022).
22. Yau, K., *et al.* Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis. *JAMA Netw Open* **4**, e2123622 (2021).
23. Moyon, Q., *et al.* BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus. *Ann Rheum Dis* **81**, 575-583 (2022).
24. Guiomar, R., *et al.* Monitoring of SARS-CoV-2 Specific Antibodies after Vaccination. *Vaccines (Basel)* **10**(2022).
25. Demircan, K., *et al.* Humoral immune response to COVID-19 mRNA vaccination in relation to selenium status. *Redox Biol* **50**, 102242 (2022).
26. Bonnet, B., *et al.* Decline of Humoral and Cellular Immune Responses Against SARS-CoV-2 6 Months After Full BNT162b2 Vaccination in Hospital Healthcare Workers. *Front Immunol* **13**, 842912 (2022).
27. Pimpinelli, F., *et al.* Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution. *J Hematol Oncol* **14**, 81 (2021).
28. Shroff, R.T., *et al.* Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors. *Nat Med* **27**, 2002-2011 (2021).
29. Chen, Y., *et al.* Dynamic SARS-CoV-2-specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine. *Clin Microbiol Infect* **28**, 410-418 (2022).
30. Zhang, J., *et al.* Differential Antibody Response to Inactivated COVID-19 Vaccines in Healthy Subjects. *Front Cell Infect Microbiol* **11**, 791660 (2021).
31. Ikezaki, H., Nomura, H. & Shimono, N. Dynamics of anti-Spike IgG antibody level after the second BNT162b2 COVID-19 vaccination in health care workers. *J Infect Chemother* (2022).
32. Palaia, I., *et al.* Pfizer-BioNTech COVID-19 Vaccine in Gynecologic Oncology Patients: A Prospective Cohort Study. *Vaccines (Basel)* **10**(2021).
33. Schrezenmeier, E., *et al.* Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis. *Front Immunol* **12**, 690698 (2021).
34. Funakoshi, Y., *et al.* Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer. *J Infect Chemother* **28**, 516-520 (2022).
35. Lucas, C., *et al.* Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. *Nature* **600**, 523-529 (2021).
36. Beilhack, G., *et al.* Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients - the Vienna Cohort. *Front Immunol* **12**, 780594 (2021).
37. Massarweh, A., *et al.* Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients with primary brain tumors: a prospective cohort study. *J Neurooncol* **156**, 483-489 (2022).


A

medRxiv preprint doi: <https://doi.org/10.1101/2022.06.11.22276266>; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).


JAPAN




B




C




D




E




F




G




A




B




C




D




E




F













G









H










**A****B****C****D****E****F**


A




B




C





D




E




**A****B**


A




B





C






D











A








B




C






**A****B****C****D****E**


A



B



C



D

